Check for updates

OPEN ACCESS

EDITED BY Somchai Amornyotin, Mahidol University, Thailand

REVIEWED BY

Mojtaba Akbari, Isfahan University of Medical Sciences, Iran Yuanyuan Mao, Fifth Affiliated Hospital of Zhengzhou University, China Stefano Turi, San Raffaele Hospital (IRCCS), Italy

*CORRESPONDENCE Peng Zhang, ⊠ anepengzhang@163.com

¹These authors have contributed equally to this work and share first authorship

RECEIVED 02 September 2023 ACCEPTED 17 June 2024 PUBLISHED 03 July 2024

CITATION

Kan Z, Min W, Dai Y and Zhang P (2024), Intravenous esketamine as an adjuvant for sedation/analgesia outside the operating room: a systematic review and meta-analysis. *Front. Pharmacol.* 15:1287761. doi: 10.3389/fphar.2024.1287761

COPYRIGHT

© 2024 Kan, Min, Dai and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Intravenous esketamine as an adjuvant for sedation/analgesia outside the operating room: a systematic review and meta-analysis

Ziheng Kan^{1†}, Weixiang Min^{2†}, Yuee Dai² and Peng Zhang^{2*}

¹School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ²Department of Anesthesiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Background: This study was conducted to evaluate the safety and efficacy of intravenous esketamine as an adjuvant for sedation or analgesia outside the operating room in adults and children.

Method: PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus were searched for potential randomized controlled studies randomized controlled trials comparing drug combinations of esketamine to any other single or combination drug regimens for sedation or analgesia outside the operating room.

Results: Twenty-five studies with a total of 3,455 participants were included in this review. The pooled results of adults showed that compared with drug regimens of the control group, intravenous esketamine combinations were significantly associated with decreased risk of oxygen desaturation (RR = 0.49, 95% CI = [0.34, 0.70]); hypotension (RR = 0.38, 95% CI = [0.31, 0.46]); bradycardia (RR = 0.23, 95% CI = [0.12, 0.43]); injection pain (RR = 0.37, 95% CI = [0.25, 0.53]); body movement (RR = 0.60, 95% CI = [0.41, 0.88]); and propofol consumption (SMD = -1.38, 95% CI = [-2.64, -0.11]), but an increased risk of psychiatric symptoms (RR = 3.10, 95% CI = [2.11, 4.54]) (RR = relative risk; CI = confidence intervals; SMD = standardized mean difference). Subgroup analysis showed that only the combination of esketamine and propofol significantly reduced the above incidence of respiratory and cardiovascular adverse events in adults. In addition, the pooled results of children showed that compared with drug regimens of the control group, esketamine and propofol co-administration significantly reduced the risk of hypotension (RR = 0.59, 95% CI = [0.37, 0.95]) but increased the risk of visual disturbance (RR = 6.62, 95% CI = [2.18, 20.13]) and dizziness (RR = 1.99, 95% CI = [1.17, 3,37]). Subgroup analysis indicated that esketamine>0.5 mg/kg significantly reduced the incidence of hypotension, but increased the risk of dizziness in children.

Conclusion: Intravenous use of esketamine, particularly in combination with propofol, may improve the safety and efficacy of sedation and analgesia outside

the operating room, although the potential for psychiatric side effects warrants attention. Future research is recommended to investigate the role of esketamine with agents other than propofol.

KEYWORDS

esketamine, sedation, analgesia, outside of operating room, propofol

1 Introduction

The need for sedation or analgesia outside the operating room is increasing because of improvements in medical technology (Pino, 2007). Various drugs such as propofol, benzodiazepines, opioids, ketamine, and dexmedetomidine, either alone or in combination, have been used (Jo and Kwak, 2019). Combination drugs help to optimize the desired effects while countering each other's side effects (Hinkelbein et al., 2020). The common administration of opioidpropofol combination and other drug combinations have been shown to be more effective than single agents for sedation or analgesia (Boriosi et al., 2017; Hayes et al., 2021; Rathi et al., 2022; De Vries et al., 2023).

Esketamine, an antagonist of the N-methyl-D-aspartic acid (NMDA) receptor, is an s-enantiomer of ketamine. It produces approximately twice higher sedative activity but induces fewer side effects than ketamine (Peltoniemi et al., 2016). Esketamine and ketamine can deliver analgosedation action, but some drawbacks such as the induction of frequent vomiting and clustered psychiatric symptoms limit their single administration (Nakao et al., 2003). Low-dose esketamine as an adjuvant has been shown to have several benefits for sedation or anesthesia, including stabilizing hemodynamics and respiratory function, decreasing propofol requirements, or reducing postoperative pain sensitivity (Huang et al., 2023).

In this study, we conducted an updated systematic review and meta-analysis to include all drug combinations of intravenous esketamine for sedation or analgesia outside the operating room. We also aimed to compare the safety and efficacy of combination regimens of esketamine with other drug regimens of the control group in adults and children undergoing various types of surgical procedures outside the operating room.

2 Materials and methods

2.1 Literature search and selection criteria

This review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2010). The PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus databases were searched for potential randomized controlled trials (RCTs) that assessed the effect of esketamine on sedation or analgesia in adults and children undergoing surgical procedures outside the operating room. The date parameters for the search were set from database inception to 19 Marc^h 2024. The search strategy was specific to each database and is available in Supplementary Material S1. Additional studies in the reference lists of selected articles were also screened for possible eligibility. Clinicaltrials.gov was also searched for possible ongoing studies. In our study, the PICOS criteria are as follows: Population (P): patients requiring sedation or analgesia in clinical settings outside the operating room; Intervention (I): intravenous administration of esketamine in combination with other sedative or analgesic agents; Comparator (C): other drug regimens without the adjunctive use of esketamine; Outcomes (O): the primary outcomes of interest were the safety of using esketamine for sedation or analgesia outside the operating room, particularly examining respiratory and cardiovascular adverse events; Study design (S): our study is based on RCTs.

The inclusion criteria were as follows: full-text available RCTs, intravenous esketamine in combination with other anesthetics, and studies with participants who had undergone sedation or analgesia outside the operating room. The exclusion criteria were as follows: failure to provide sufficient information or data, sedation performed in the ICU or emergency room, or studies with participants under general anesthesia with laryngeal insertion or tracheal intubation.

2.2 Data collection

Two independent authors extracted data from the included studies based on a previously designed data extraction table. The following information was extracted: author, publication year, number of participants, age, intervention measures, type of surgery, and outcomes. The primary outcomes were respiratory and cardiovascular adverse events. The secondary outcomes were injection pain, inadequate sedation parameters (intraoperative cough and body movement), nausea and/or vomiting, propofol consumption, psychiatric symptoms, visual disturbance, dizziness, emergence delirium, awakening time, recovery time, and orientation recovery time. Where data were presented as values other than the mean and standard deviations, we attempted to contact the author to obtain raw data. If this was not possible, data were excluded from the meta-analysis. In the case of studies with more than one treatment group (including different doses of esketamine), we combined different doses as the esketamine≤0.5 mg/kg subgroup or esketamine>0.5 mg/kg subgroup (Higgins and Deeks, 2011). The risk of bias of the included studies was also independently assessed by two reviewers using the Cochrane risk of bias tool. Five parameters, namely, randomization sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting, from each included study were evaluated as low, unclear, or high risk of bias. The database searching, literature screening, data collection and risk of bias assessment were conducted independently by two authors, ZK and WM. Any discrepancies were resolved by discussion with the third author, PZ.

2.3 Statistical analysis

The relative risk (RR) with 95% confidence intervals (CI) was calculated for dichotomous data. The standardized mean difference (SMD) with 95% CI was used to express continuous variables owing to differences in measurement scales and methods of drug administration across included studies. Differences were considered statistically significant if p < 0.05, 95%CI of RR excluded 1, or 95% CI excluded 0 for the SMD. The I² statistic was used to assess heterogeneity. If heterogeneity was significant (I²>50%), a random effects model was used; otherwise, a fixed effects model was used. Subgroup analysis was conducted according to the esketamine drug regimens (esketamine combined with propofol or other drugs) and esketamine dose ($\leq 0.5 \text{ mg/kg or } > 0.5 \text{ mg/kg}$). We did not perform subgroup analysis if there were fewer than two trials in each subgroup. Additionally, sensitivity analysis was performed by omitting one study each time for primary outcomes to identify potential sources of heterogeneity. Publication bias was assessed by visual inspection of funnel plots. Statistical analyses were performed using Review Manager (RevMan) version 5.1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011).

3 Results

3.1 Study search and characteristics

The electronic search yielded a total of 4,830 citations. After excluding 2096 duplicates, 2,734 studies were screened. After screening the titles and abstracts and assessing the full texts, 25 studies with a total of 3,455 participants were finally included in this review. A flowchart of the literature search for the included studies is shown in Figure 1. The data of 44 studies excluded by full-text screening are available in Supplementary Material S2.

Six studies involved 698 pediatric participants (age range: 2 days to 12 years) (Pees et al., 2003; Wang et al., 2022; Xu (b) et al., 2022; Zheng (b) et al., 2023; Zheng et al., 2022; Zhong et al., 2023), and the 19 remaining studies involved 2,757 adult participants (18-89 years) (Chen et al., 2022; Chen et al., 2023; Cui et al., 2023; Eberl et al., 2020; Feng (a) et al., 2022; Feng (b) et al., 2022; Lin et al., 2023; Liu et al., 2023; Lu et al., 2022; Ma et al., 2024; Nie et al., 2023; Si et al., 2024; Song et al., 2023; Wang et al., 2019; Xin et al., 2024; Xu (a) et al., 2022; Yang et al., 2022; Zhan et al., 2022; Zheng (a) et al., 2023). Fifteen studies carried out diagnostic and therapeutic gastrointestinal endoscopy (Chen et al., 2023; Eberl et al., 2020; Feng (a) et al., 2022; Liu et al., 2023; Lu et al., 2022; Ma et al., 2024; Song et al., 2023; Wang et al., 2022; Wang et al., 2019; Xu (a) et al., 2022; Yang et al., 2022; Zhan et al., 2022; Zheng (a) et al., 2023; Zheng (b) et al., 2023; Zheng et al., 2022); four conducted fiberoptic bronchoscopy (Cui et al., 2023; Feng (b) et al., 2022; Nie et al., 2023; Zhong et al., 2023); and six studies involved abortions (Chen et al., 2022), cervical conization (Si et al., 2024), MRI (Xu (b) et al., 2022), cardiac catheterization (Pees et al., 2003), dental extraction (Xin et al., 2024), and percutaneous radiofrequency ablation of lung tumor (Lin et al., 2023), respectively. Twenty-two studies used a combination of esketamine and propofol (Chen et al., 2022; Chen et al., 2023; Cui et al., 2023; Eberl et al., 2020; Feng (a) et al., 2022; Feng (b) et al., 2022; Liu et al., 2023; Ma et al., 2024; Nie et al., 2023;



Si et al., 2024; Song et al., 2023; Wang et al., 2022; Wang et al., 2019; Xin et al., 2024; Xu (a) et al., 2022; Xu (b) et al., 2022; Yang et al., 2022; Zhan et al., 2022; Zheng (a) et al., 2023; Zheng (b) et al., 2023; Zheng et al., 2022; Zhong et al., 2023), two studies used esketamine plus benzodiazepines (Pees et al., 2003; Lu et al., 2022), and one study used esketamine combined with dexmedetomidine (Lin et al., 2023). Eighteen studies involved one esketamine group with doses ranging from 0.15 to 1.0 µg/kg (Cui et al., 2023; Eberl et al., 2020; Feng (b) et al., 2022; Lin et al., 2023; Liu et al., 2023; Lu et al., 2022; Ma et al., 2024; Nie et al., 2023; Pees et al., 2003; Si et al., 2024; Song et al., 2023; Wang et al., 2019; Xin et al., 2024; Xu (a) et al., 2022; Xu (b) et al., 2022; Zheng (a) et al., 2023; Zheng (b) et al., 2023; Zhong et al., 2023), and seven studies involved more than one esketamine group with doses ranging from 0.05 to 1.0 µg/kg (Chen et al., 2022; Chen et al., 2023; Feng (a) et al., 2022; Wang et al., 2022; Yang et al., 2022; Zhan et al., 2022; Zheng et al., 2022). With respect to drug regimens in the control groups, 10 studies used propofol alone (Cui et al., 2023; Feng (a) et al., 2022; Liu et al., 2023; Nie et al., 2023; Wang et al., 2022; Yang et al., 2022; Zhan et al., 2022; Zheng (a) et al., 2023; Zheng (b) et al., 2023; Zheng et al., 2022); 13 studies used propofol in combination with opioids (Chen et al., 2022; Chen et al., 2023; Eberl et al., 2020; Feng (b) et al., 2022; Lu et al., 2022; Ma et al., 2024; Si et al., 2024; Song et al., 2023; Xu (a) et al., 2022; Zhong et al., 2023), ketamine (Wang et al., 2019), or dexmedetomidine (Xin et al.,

TABLE 1 The characteristics of the included studies.

No.	Study	Procedure	No.	Age	Treatment group	Control group	Outcomes
1	Zhan et al. (2022)	Gastrointestinal endoscopy	260	18–60y	esketamine (0.05, 0.1, 0.2 ug/kg) + propofol 1.5 mg/kg	propofol 1.5 mg/kg	propofol consumption, procedure time, induction time, SBP, DBP, HR, SpO ₂ , awakening delay, orientation recovery time, adverse events, psychotomimetic effects, MMSE
2	Zheng et al. (2022)	diagnostic upper gastrointestinal endoscopy	92	3–12y	esketamine (0.25, 0.5, 1.0 ug/kg) + propofol	propofol	ED50 of propofol, propofol doses, awakening time, examination time, MAP, HR, adverse events, physician and patient satisfaction
3	Feng (a) 2022	Gastrointestinal endoscopy	100	18-65y	esketamine (0.15, 0.25, 0.5 ug/kg) + propofol TCI	propofol TCI	EC50 of propofol, propofol doses, procedure time, awakening time, MAP, HR, adverse effects
4	Yang et al. (2022)	gastrointestinal endoscopy	90	65-89у	esketamine (0.25, 0.5 ug/kg) + propofol	propofol TCI	EC50 of propofol, change of MAP and HR, recovery time, procedure time, patient and gastroenterologist satisfaction, adverse effects, psychotomimetic effects
5	Wang et al. (2022)	gastro-duodenoscopy	120	6-12y	esketamine (0.3, 0.5, 0.7 ug/kg) + propofol 3 mg/kg	propofol 3 mg/kg	procedure duration, number of cases with smooth placement of first endoscope insertion, times of additional propofol, propofol dose, recovery time, PACU stay, endoscopist satisfaction rate, MAP, HR, BIS, adverse events
6	Lu et al. (2022)	gastroenteroscopy	106	20-75y	esketamine 1.0 ug/kg + remimazolam 0.3–0.4 mg/kg	sufentanil 0.1 ug/kg + propofol	induction time, awakening time, orientation recovery time, adverse effects
7	Ma et al. (2024)	endoscopic resection in colorectum	166	>18y	propofol TCI 1.5–2.5 mg/mL + esketamine 0.15 mg/kg	propofol TCI 1.5–2.5 mg/ mL + fentanyl 1ug/kg	propofol consumption, vasoactive drug dosages, sedation-related times, adverse events, and satisfaction
8	Si et al. (2024)	cervical conization	122	18-60	esketamine 0.15 mg/kg + sufentanil 0.1ug/kg +propofol	sufentanil 0.2ug/kg + propofol	incidence and severity of SRAEs, effectiveness of sedation, awakening time, psychotomimetic side effects, postoperative pain, PONV, and patient and gynaecologist satisfaction
9	Feng (b) 2022	fibronchoscopy	80	>65y	esketamine 0.15 ug/kg + propofol	sufentanil 0.1ug/kg+ propofol	MAP, HR and SpO ₂ , propofol dose, examination time, wake- up time, VAS score, adverse reactions
10	Chen et al. (2022)	abortion	178	18–45y	esketamine (0.2, 0.25, 0.3 ug/kg) + propofol	fentanyl 1 mg/kg + propofol 2 mg/kg	incidence of complications, MAP, HR, SpO2, surgery time, induction time, recovery time, dischargeable time, frequency of additional propofol, propofol dose, satisfaction (patient, surgeon, anesthesiologist), postoperative pain
11	Xu (a) 2022	gastroscopy	87	18-64y	esketamine 0.3 ug/kg + propofol	dezocine 0.05 mg/kg+ propofol	total dose of propofol, endoscopy time, recovery time, endoscopist and patient satisfaction, MAP, HR, SpO2, side effects

(Continued on following page)

TABLE 1 (Continued) The characteristics of the included studies.

No.	Study	Procedure	No.	Age	Treatment group	Control group	Outcomes
12	Eberl et al. (2020)	ERCP	162	>18y	esketamine 0.15 ug/kg + propofol (TCI)	alfentanil 2ug/kg + propofol (TCI)	procedure duration, propofol dose, recovery time, patient and endoscopist satisfaction, patient recommendation, endoscopist perception of patient pain, side effects
13	Wang et al. (2019)	gastroscopy	32	32 ± 6.19y; 40 ± 8.91y	esketamine 0.5 ug/kg + propofol	ketamine 1 mg/kg+ propofol 0.6 mg/kg	pharmacokinetics parameters, recovery time, orientation recovery time, adverse reactions
14	Pees et al. (2003)	Cardiac catheterization	100	2 days-11y	esketamine 1.0 ug/kg + midazolam	ketamine 1 mg/kg + midazolam 0.5 mg/kg	dosage of S- and R-ketamine, nausea and vomiting, sleeping time, further sedative medication after awakening to suppress psychotic reactions and/or heavy body movements
15	Xu et al. (2022)	MRI	114	6months- 8 y	esketamine 0.15 ug/kg + propofol	dexmedetomidine 0.3ug/kg + propofol 1.5 mg/kg	propofol dose, adverse reactions, time to emergence from sedation, time to discharge from recovery room, HR, SBP, DBP, scanning time, radiologist and parent satisfaction scores, Ramsey sedation score
16	Chen et al. (2023)	endoscopic variceal ligation	100	18–70y	esketamine (0.2, 0.3, 0.4 ug/kg) + propofol 1.5 mg/kg	sufentanil 0.1 µg/kg + propofol 1.5 mg/kg	Adverse events, SBP, DBP, MAP, HR, TV, RR, MV, SpO2, operative time, awake time, propofol dose, number of additional propofol dosages, airway excreta, pain NRS, patient and endoscopic physicians satisfaction
17	Zheng et al. (2022)	gastroscopy	113	18-64y	esketamine 0.25 ug/kg + propofol	propofol	propofol consumption, induction time, awakening times, SBP, DBP, HR, SpO2, duration of procedure, orientation recovery time, adverse events, endoscopist and anesthesiologist satisfaction score
18	Zheng (b) 2023	gastrointestinal endoscopy	200	3–12y	esketamine 0.5 mg/kg + propofol 2 mg/kg	nalbuphine 0.2 mg/kg + propofol 2 mg/kg	success rate of the endoscope insertion, HR, MAP respiratory depression, examination and awakening time, physician and patient satisfaction, awakening period and 24 h after examination complicates, PAED scale
19	Zhong et al. (2023)	flexible fibreoptic bronchoscopy	72	<12y	esketamine 0.3 mg/kg +propofol 2–2.5 mg/kg, esketamine 0.3 mg/kg/h, propofol 4–10 mg/kg/h, remifentanil 0.05–0.3ug/kg/min for continuous infusion	propofol 2–2.5 mg/kg, continuous infusion drugs as same as treatment group	oxygen desaturation, intraoperative hemodynamics, duration of induction, procedure and anesthesia, recovery time, the time to the ward from the recovery room, dose of propofol and remifentanil, number of times propofol was added, PAED scores, cough scores, injection pain, laryngospasm, bronchospasm, PONV, vertigo, hallucination, agitation
20	Nie et al. (2023)	fiberoptic bronchoscopy	84	18–65y	esketamine 0.2 mg/kg +propofol 1.5 mg/kg	remifentanil 0.5ug/kg + propofol 1.5 mg/kg	intraoperative hemodynamics, dose of propofol, number of patients used additional propofol, times of giving additional propofol, adverse events, recovery of consciousness, awaken time, duration of examination, satisfaction of patients and bronchoscopists

(Continued on following page)

TABLE 1 (Continued)	The	characteristics	of	the	included	studies.
---------------------	-----	-----------------	----	-----	----------	----------

No.	Study	Procedure	No.	Age	Treatment group	Control group	Outcomes
21	Cui et al. (2023)	endobronchial ultrasound-guided transbronchial needle aspiration	140	18-89y	esketamine 0.3 mg/kg + propofol TCI, esketamine 0.2 mg/kg/h for sedative maintenance	propofol TCI	MAP, lidocaine dose, times of lidocaine sprays, cough score, propofol dosage, patient satisfaction, endoscopist satisfaction, sedation-related adverse and recovery time
22	Liu et al. (2023)	gastroscopy	80	18-64y	esketamine 0.2 mg/kg +propofol 1 mg/kg	propofol 1 mg/kg	total amount of propofol, incidences of injection pain, involuntary movement, hemodynamic and respiratory adverse events during examination, total examination time, recovery time and postoperative adverse effects
23	Lin et al. (2023)	lung tumor percutaneous radiofrequency ablation	44	37-84y	esketamine 0.2 mg/kg + dexmedetomidine 1 μg/kg	sufentanil 0.1ug/kg + dexmedetomidine 1 μg/kg	MOAAS, physical movement pain scale, vital signs, recovery time, radiologist and patient satisfaction, respiratory depression and PONV
24	Xin et al. (2024)	dental extraction	150	<60y	propofol 0.5 mg/kg+ esketamine 0.25 mg/kg, then propofol 2.5 mg/kg/h for maintenance for both groups	propofol 0.5 mg/kg+ dexmedetomidine 0.5–1.0 mg/kg/h or propofol 0.5 mg/kg alone	vital signs, blood gas analysis, BIS, adverse reactions, recovery time, patient satisfaction, and doctor satisfaction
25	Song 2023	bidirectional endoscopy	663	18–70y	esketamine 0.15 mg/kg + sufentanil 0.1 μg/kg + propofol 0.5 mg/kg	sufentanil 0.1 µg/kg + propofol 0.5 mg/kg	Desaturation, hypotension, propofol requirements, postprocedure pain, fatigue, nausea or vomiting, dizziness or headache, hallucination or nightmare, endoscopist satisfaction, and patient satisfaction

2024; Xu (b) et al., 2022); one study used ketamine and midazolam (Pees et al., 2003); and one study used sufentanil in combination with dexmedetomidine (Lin et al., 2023). The characteristics of the included studies are shown in Table 1.

Fourteen studies had an overall low risk of bias, 10 studies had an unclear risk of bias, and one study had a high risk of bias. The sources of bias were primarily because of poor reporting of the randomization process and blinding, specifically a lack of description about allocation concealment. The risk of bias of the included studies is presented in Table 2.

3.2 Pooled results of adults

The pooled results in adults showed that compared with drug regimens of the control group, intravenous esketamine drug combinations significantly reduced the risk of oxygen desaturation (RR = 0.49, 95%CI = [0.34, 0.70], p < 0.0001); hypotension (RR = 0.38, 95%CI = [0.31, 0.46], p < 0.00001); bradycardia (RR = 0.23, 95%CI = [0.12, 0.43], p < 0.00001); injection pain (RR = 0.37, 95%CI = [0.25, 0.53], p < 0.00001); body movement (RR = 0.60, 95%CI = [0.41, 0.88], p = 0.009); and propofol consumption (SMD = -1.38, 95%CI = [-2.64, -0.11], p = 0.03) but increased the risk of psychiatric symptoms (RR = 3.10, 95% CI = [2.11, 4.54], p < 0.00001). No significant differences were found in hypertension (RR = 1.75, 95%CI = [0.75, 4.06], p = 0.19);

tachycardia (RR = 1.72, 95%CI = [0.76, 3.93], p = 0.20); arrhythmia (RR = 0.14, 95%CI = [0.01, 2.67], p = 0.19); cough (RR = 0.66, 95%CI = [0.33, 1.31], p = 0.24); nausea and/or vomiting (RR = 0.76, 95%CI = [0.56, 1.02], p = 0.07); dizziness (RR = 1.19, 95% CI = [0.83, 1.71], p = 0.34); awakening time (SMD = 0.13, 95%CI = [-0.59, 0.85], p = 0.73); recovery time (SMD = -0.11, 95%CI = [-0.58, 0.35], p = 0.63); or orientation recovery time (SMD = -0.05, 95%CI = [-0.21, 0.12], p = 0.56) compared with drug regimens of the control group (Figures 2A–D; Table 3).

Subgroup analysis of esketamine regimens showed a significant reduction in the risk of oxygen desaturation (RR = 0.51, 95%CI = [0.35, 0.74], p = 0.0003; hypotension (RR = 0.38, 95%CI = [0.31, 0.35]0.46], *p* < 0.00001); and bradycardia (RR = 0.24, 95%CI = [0.12, (0.47], p < 0.0001) in the esketamine-propofol combination, and a marginally significant reduction (oxygen desaturation: RR = 0.23, 95%CI = [0.05, 1.06], p = 0.06, and test for subgroup differences p =0.32; *hypotension*: RR = 0.26, 95%CI = [0.07, 1.00], *p* = 0.05, and test for subgroup differences p = 0.59; bradycardia: RR = 0.14, 95%CI = [0.02, 1.12], p = 0.06, and test for subgroup differences p = 0.64) in the esketamine-non-propofol combination in adults. No significant difference was found in nausea and/or vomiting in the subgroup analysis of esketamine regimens (Table 4). Given that only one study involved esketamine dose >0.5 ug/kg (Lu et al., 2022), we did not perform subgroup analysis of the esketamine dose in adults. Additionally, the pooled results of adults were not altered after eliminating this single esketamine>0.5 ug/kg study (data not shown).

TABLE 2 The risk of bias of the included studies.

Study	Random	Allocation	Blinding of	Blinding of	Incomplete	Selective
etaay	sequence generation	concealment	participants and personnel	outcome assessment	outcome data	reporting
Zhan et al. (2022)	low	low	low	low	low	low
Xu (a) 2022	low	unclear	low	low	low	low
Lu et al. (2022)	low	unclear	unclear	unclear	low	low
Zheng et al. (2022)	low	low	low	low	low	low
Feng (a) 2022	low	low	low	low	low	low
Wang et al. (2019)	low	low	unclear	unclear	low	low
Yang et al. (2022)	low	unclear	unclear	low	low	low
Wang et al. (2022)	low	low	low	low	low	low
Feng (b) 2022	low	unclear	unclear	unclear	low	low
Eberl et al. (2022)	low	low	low	low	low	low
Xu (b) 2022	low	low	low	low	low	low
Pees et al. (2003)	unclear	unclear	unclear	low	high	unclear
Chen et al. (2022)	low	low	low	low	low	low
Chen et al. (2023)	low	low	low	low	low	low
Zheng (a) 2023	low	low	low	low	low	low
Zheng (b) 2023	low	low	low	low	low	low
Zhong et al. (2023)	low	low	low	low	low	low
Nie et al. (2023)	low	unclear	low	unclear	low	low
Cui et al. (2023)	low	low	low	low	low	low
Liu et al. (2023)	low	low	low	low	low	low
Lin et al. (2023)	low	unclear	low	low	low	low
Xin et al. (2024)	unclear	unclear	unclear	unclear	low	low
Song 2023	low	low	low	low	low	low
Ma et al. (2024)	low	unclear	low	low	low	low
Si et al. (2024)	low	unclear	low	low	low	low

A 1. Oxygen desaturation

	Esketar	nine	Contr	lor		Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M–H, Random, 95% CI
Chen 2022	2	133	5	45	3.6%	0.14 [0.03, 0.67]	
Chen 2023	6	75	8	25	6.9%	0.25 [0.10, 0.65]	
Cui 2023	4	68	8	67	5.7%	0.49 [0.16, 1.56]	
Eberl 2020	11	83	8	79	7.7%	1.31 [0.56, 3.08]	
Feng (a) 2022	8	75	5	25	6.5%	0.53 [0.19, 1.48]	
Feng (b) 2022	2	40	12	40	4.3%	0.17 [0.04, 0.70]	
Lin 2023	1	22	2	22	2.0%	0.50 [0.05, 5.12]	
Liu 2023	5	38	3	38	4.6%	1.67 [0.43, 6.49]	
Lu 2022	1	53	8	53	2.5%	0.13 [0.02, 0.96]	· · · · · · · · · · · · · · · · · · ·
Ma 2024	12	81	20	79	9.6%	0.59 [0.31, 1.12]	
Nie 2023	0	42	0	42		Not estimable	
Si 2024	14	60	38	60	10.9%	0.37 [0.22, 0.61]	
Song 2023	12	331	31	329	9.5%	0.38 [0.20, 0.74]	
Xin 2024	2	50	12	100	4.2%	0.33 [0.08, 1.43]	
Xu (a) 2022	1	42	2	41	2.0%	0.49 [0.05, 5.18]	
Zhan 2022	55	195	14	65	10.8%	1.31 [0.78, 2.19]	
Zheng (a) 2023	9	52	21	52	9.2%	0.43 [0.22, 0.85]	
Total (95% CI)		1440		1162	100.0%	0.49 [0.34, 0.70]	•
Total events	145		197				
Heterogeneity: Tau ² =	= 0.24; Ch	$i^2 = 32$.33, df =	15 (P	= 0.006)	$ l^2 = 54\%$	0.01 0.1 1 10 100
Test for overall effect	Z = 3.90	(P < 0	.0001)				0.01 0.1 1 10 100 Favours [experimental] Favours [control]

2. Hypotension

	Esketar	nine	Conti	rol		Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Chen 2022	0	133	9	45	5.2%	0.02 [0.00, 0.30]	· · · · · · · · · · · · · · · · · · ·
Chen 2023	20	75	18	25	9.9%	0.37 [0.24, 0.58]	
Cui 2023	11	68	14	67	5.2%	0.77 [0.38, 1.58]	
Eberl 2020	10	83	17	79	6.4%	0.56 [0.27, 1.15]	
Feng (a) 2022	2	75	13	25	7.2%	0.05 [0.01, 0.21]	
Lin 2023	2	22	5	22	1.8%	0.40 [0.09, 1.85]	
Liu 2023	2	38	14	38	5.2%	0.14 [0.03, 0.59]	
Lu 2022	0	53	4	53	1.7%	0.11 [0.01, 2.01]	• • • •
Ma 2024	27	81	52	79	19.4%	0.51 [0.36, 0.72]	
Si 2024	8	60	17	60	6.3%	0.47 [0.22, 1.01]	
Song 2023	16	331	44	329	16.2%	0.36 [0.21, 0.63]	
Xin 2024	1	50	3	100	0.7%	0.67 [0.07, 6.25]	
Xu (a) 2022	2	42	7	41	2.6%	0.28 [0.06, 1.26]	
Yang 2022	0	60	3	30	1.7%	0.07 [0.00, 1.36]	· · · · · · · · · · · · · · · · · · ·
Zhan 2022	15	195	11	65	6.1%	0.45 [0.22, 0.94]	
Zheng (a) 2023	4	52	12	52	4.4%	0.33 [0.11, 0.97]	
Total (95% CI)		1418		1110	100.0%	0.38 [0.31, 0.46]	•
Total events	120		243		2.00/		
Heterogeneity: Chi ² =); 1° =	39%		0.01 0.1 1 10 100
Test for overall effect:	Z = 9.97	(P < 0	.00001)				Favours [experimental] Favours [control]

3. Bradycardia



3.3 Pooled results of children

The pooled results in children showed that compared with drug regimens of the control group, esketamine-propofol combination

significantly reduced the risk of hypotension (RR = 0.59, 95%CI = [0.37, 0.95], p = 0.03) and increased the risk of visual disturbance (RR = 6.62, 95%CI = [2.18, 20.13], p = 0.0009) and dizziness (RR = 1.99, 95%CI = [1.17, 3,37], p = 0.01). No significant differences were

B 4. Hypertension

Study or Subgroup	Esketan Events		Contro Events		Weight	Relative Risk M–H, Random, 95% CI	Relative Risk M–H, Random, 95% Cl
Chen 2023	9	75	3	25	17.0%	1.00 [0.29, 3.41]	
Cui 2023	3	68	4	67	14.8%		
	17	83	17	79	23.5%	0.74 [0.17, 3.18]	
Eberl 2020						0.95 [0.52, 1.73]	
Lin 2023	5	22	0	22	6.6%	11.00 [0.64, 187.67]	
Liu 2023	9	38	0	38	6.7%	19.00 [1.15, 315.26]	
Ma 2024	0	81	0	79		Not estimable	
Wang 2019	1	16	2	16	8.9%	0.50 [0.05, 4.98]	
Xin 2024	10	50	3	100	16.8%	6.67 [1.92, 23.15]	
Xu (a) 2022	0	42	0	41		Not estimable	
Zhan 2022	1	195	0	65	5.5%	1.01 [0.04, 24.50]	
Total (95% CI)		670		532	100.0%	1.75 [0.75, 4.06]	-
Total events	55		29				
Heterogeneity: Tau ² = Test for overall effect	0.69; Chi		.96, df = 7	7 (P =)	0.03); I²	= 56%	0.01 0.1 1 10 100 Favours [experimental] Favours [control]
. Tachycardia							
	Esketan		Contro			Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events T	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Chen 2023	29	75	7	25	23.2%	1.38 [0.69, 2.75]	
Cui 2023	2	68	5	67	13.5%	0.39 [0.08, 1.96]	
Eberl 2020	17	83	16	79	24.1%	1.01 [0.55, 1.86]	
			3				
Liu 2023	19	38		38	18.2%	6.33 [2.04, 19.64]	
Ma 2024	0	81	1	79	5.4%	0.33 [0.01, 7.87]	
Xin 2024	7	50	0	100	6.4%	29.71 [1.73, 509.89]	
Xu (a) 2022	3	42	1	41	9.2%	2.93 [0.32, 27.02]	
Total (95% CI)		437		429	100.0%	1.72 [0.76, 3.93]	-
Total events	77		33				
Heterogeneity: Tau ² =	0.64; Ch	$^{2} = 16$.84, df = 6	5 (P =)	0.010); I	$^{2} = 64\%$	0.01 0.1 1 10 100
Test for overall effect	Z = 1.30	(P = 0.	20)				Favours [experimental] Favours [control]
	Esketa	mine	Cont	Innt		Relative Risk	Relative Risk
Study or Subgroup	Esketa Events	Tota		Tota		Relative Risk ht M-H, Random, 95 0% 0.14 [0.01, 2	5% CI M-H, Random, 95% CI
Cui 2023	Events 0	Tota 6	al Events 8 3	Tota 6	7 100.	ht M-H, Random, 95	5% CI M-H, Random, 95% CI 2.67]
	Events	Tota 6	al Events 8 3	Tota 6	7 100.	ht M-H, Random, 95	5% CI M-H, Random, 95% CI 2.67]
Cui 2023 Zhan 2022	Events 0	Tot 6 19	al Events 8 3 5 0	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% CI M-H, Random, 95% CI 2.67] 4
Cui 2023 Zhan 2022 Total (95% CI)	Events 0 0	Tota 6 19 26	al Events 8 3 5 0 3	Tota 6 6	7 100.	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% CI M-H, Random, 95% CI 2.67] 4
Cui 2023 Zhan 2022 Total (95% CI) Total events	Events 0 0	Tota 6 19 26	al Events 8 3 5 0	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% CI M-H, Random, 95% CI 2.67] 4
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a	Events 0 0 0 0 pplicable	Tota 6 19 26	al Events 8 3 5 0 3 3	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% Cl M−H, Random, 95% Cl 2.67] able 2.67] 0.01 0.1 1 10 100
Cui 2023 Zhan 2022 Total (95% CI) Total events	Events 0 0 0 0 pplicable	Tota 6 19 26	al Events 8 3 5 0 3 3	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% CI M-H, Random, 95% CI 2.67] 2.67]
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a	Events 0 0 0 0 pplicable	Tota 6 19 26	al Events 8 3 5 0 3 3	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% Cl M−H, Random, 95% Cl 2.67] able 2.67] 0.01 0.1 1 10 100
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec	Events 0 0 0 0 pplicable	Tota 6 19 26	al Events 8 3 5 0 3 3	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% Cl M−H, Random, 95% Cl 2.67] able 2.67] 0.01 0.1 1 10 100
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec	Events 0 0 0 0 pplicable	Tota 6 19 26	al Events 8 3 5 0 3 3	Tota 6 6	7 100. 5	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim	5% Cl M−H, Random, 95% Cl 2.67] able 2.67] 0.01 0.1 1 10 100
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec	Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Tot: 6 19 26	al Events 8 3 5 0 3 3 0.19)	Tota 6 6	7 100. 5	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2	5% CI M-H, Random, 95% CI 2.67] 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec '. Injection pain	Events 0 0 pplicable t: Z = 1.3 Esketa	Tot: 6 19 26 1 (P =	al Events 8 3 5 0 3 0.19) Control	Tota 6 6 13	7 100. 5 2 100.0	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 Relative Risk	5% Cl M−H, Random, 95% Cl 2.67] able 2.67] 0.01 0.1 1 10 100
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effec '. Injection pain Study or Subgroup	Events 0 0 pplicable t: Z = 1.3 Esketai Events	Tota 6 19 26 1 (P = Total	al Events 8 3 5 0 3 0.19) Contro Events	Tota 6 13 01 Total	7 100.05 2 100.0	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 Relative Risk t M-H, Fixed, 95% CI	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023	Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Tota 6 19 26 1 (P = <u>Total</u> 38	al Events 8 3 5 0 3 0.19) Contro Events 13	ol Total 38	7 100.0 5 2 100.0 Weight 17.3%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023 Lu 2022	Events 0 0 pplicable t: Z = 1.3 Esketau Events 0	Tota 6 19 26 1 (P = 1 (P = <u>Total</u> 38 53	al Events 8 3 5 0 3 0.19) Contro Events 13 13	ol 701 701 701 701 701 701 701 701 701 701	7 100.0 5 2 100.0 Weight 17.3% 18.0%	ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Lu 2022 Xu (a) 2022	Events 0 0 0 0 0 0 0 0 0 0 1 5 0 0 1	Tota 6 19 26 1 (P = 1 (P = Total 38 53 42	al Events 8 3 5 0 3 0.19) Contro Events 13 13 2	ol Total 38 53 41	7 100. 5 2 100. Weight 17.3% 18.0% 2.7%	Int M-H, Random, 95 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.097] 0 0.40 [0.00, 0.61] 0 0.49 [0.05, 5.18]	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022 Zhan 2022	Events 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 10	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195	al Events 8 3 5 0 3 3 0.19) Contru Events 13 13 2 3	ol Total 38 53 41 65	7 100.0 5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Lu 2022 Xu (a) 2022	Events 0 0 0 0 0 0 0 0 0 0 1 5 0 0 1	Tota 6 19 26 1 (P = 1 (P = Total 38 53 42	al Events 8 3 5 0 3 3 0.19) Contru Events 13 13 2 3	ol Total 38 53 41	7 100. 5 2 100. Weight 17.3% 18.0% 2.7%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Luu 2022 Xu (a) 2022 Zhan 2022 Zheng (a) 2023	Events 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 10	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42	Tota 6 6 13 13 13 13 13 13 13 13 13 13 13 13 13	7 100. 5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 56.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022	Events 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 10	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42	Tota 6 6 13 13 13 13 13 13 13 13 13 13 13 13 13	7 100.0 5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 5 0 0.03 [0.15, 0.097] 0 0.04 [0.00, 0.61] 0 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58]	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effec '. Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022 Zhan 2022 Zheng (a) 2023 Total (95% Cl)	Events 0 0 pplicable t: Z = 1.3 Esketau Events 5 0 1 1 10 16	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42	Tota 6 6 13 13 13 13 13 13 13 13 13 13 13 13 13	7 100. 5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 56.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	5% CI M-H, Random, 95% CI 2.67] 2.67] 0.01 0.1 1 10 100 Esketamine Control Relative Risk
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect '. Injection pain Study or Subgroup Liu 2023 Luu 2022 Xu (a) 2022 Zhan 2022 Zheng (a) 2023	Events 0 0 0 0 0 0 0 0 0 0 1 5 0 1 1 0 0 16 32	Toti 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52 380	al Events 8 3 5 0 3 3 0.19) Contru Events 13 13 2 3 42 73	ol Total 38 53 41 65 52 249	7 100.5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 100.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	5% Cl M-H, Random, 95% Cl 2.67]
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023 Lu 2022 Xu (a) 2022 Zhan 2022 Zheng (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² =	Events 0 0 0 0 0 0 0 0 0 1 10 16 32 5 5.66, df	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52 380 = 4 (P	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ²	ol Total 38 53 41 65 52 249	7 100.5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 100.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	Big CI M-H, Random, 95% CI 2.67] Image: Control for the second seco
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023 Lu 2022 Xu (a) 2022 Zhang (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² =	Events 0 0 0 0 0 0 0 0 0 1 10 16 32 5 5.66, df	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52 380 = 4 (P	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ²	ol Total 38 53 41 65 52 249	7 100.5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 100.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	5% Cl M-H, Random, 95% Cl 2.67]
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effec . Injection pain Study or Subgroup Liu 2023 Lu 2022 Xu (a) 2022 Zhang (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² =	Events 0 0 0 0 0 0 0 0 0 1 10 16 32 5 5.66, df	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52 380 = 4 (P	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ²	ol Total 38 53 41 65 52 249	7 100.5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 100.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	Big CI M-H, Random, 95% CI 2.67] Image: Control for the second seco
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhan 2022 Zhan 2022 Zheng (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect	Events 0 0 0 0 0 0 0 0 0 1 10 16 32 5 5.66, df	Tota 6 19 26 1 (P = <u>Total</u> 38 53 42 195 52 380 = 4 (P	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ²	ol Total 38 53 41 65 52 249	7 100.5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 100.0%	Ht M-H, Random, 95 0% 0.14 [0.01, 2 Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.07] 0 0.40 [0.00, 0.61] 0 0.40 [0.00, 0.51] 0 1.11 [0.32, 3.91] 0 0.38 [0.25, 0.58]	Big CI M-H, Random, 95% CI 2.67] Image: Control for the second seco
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhan 2022 Zhan 2022 Zhan 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect	Events 0 0 0 0 0 0 0 0 0 1 10 16 2 5.35 0 1 10 16 2 5.35	Tota 6 19 26 1 (P = Total 38 53 42 52 380 = 4 (P (P < 0))	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ²	Total 6 13 7 7 8 53 41 65 52 249 2	7 100.5 2 100.0 Weight 17.3% 18.0% 2.7% 6.0% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0.04 [0.00, 0.61] 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58] 0.37 [0.25, 0.53] 0.37 [0.25, 0.53]	6% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhan 2022 Zheng (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect	Events 0 0 0 0 0 0 0 0 1 1 0 16 2 2 5.66, df 2 2 5.35 0 1 10 16 2 2 5.35 0 1 10 16 2 5 5.35 17 10 16 16 16 16 16 16 16 17 17 16 16 16 16 16 17 17 17 17 17 17 17 17 17 17 17 17 17	Tota 6 19 26 1 (P = Total 388 53 42 195 52 380 = 4 (P < 0 + (P < 0) hine	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² Contro	Total 66 13 53 41 65 52 249 2 49	7 100.1 5 2 100.0 2 100.0 2 100.0 3 2 100.0 5 6.0% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.14 [0.01, 2 0 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0 0.40 [0.00, 0.61] 0 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58] 0 0.37 [0.25, 0.53] Relative Risk Relative Risk	6% Cl M-H, Random, 95% Cl 2.67]
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhan 2022 Zheng (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect	Events 0 0 0 0 0 0 0 0 1 1 0 16 2 2 5.66, df 2 2 5.35 0 1 10 16 2 2 5.35 0 1 10 16 2 5 5.35 17 10 16 16 16 16 16 16 16 17 17 16 16 16 16 16 17 17 17 17 17 17 17 17 17 17 17 17 17	Tota 6 19 26 1 (P = Total 388 53 42 195 52 380 = 4 (P < 0 + (P < 0) hine	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² Contro	Total 66 13 53 41 65 52 249 2 49	7 100.1 5 2 100.0 2 100.0 2 100.0 3 2 100.0 5 6.0% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0.04 [0.00, 0.61] 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58] 0.37 [0.25, 0.53] 0.37 [0.25, 0.53]	6% Cl M-H, Random, 95% Cl 2.67]
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhan 2022 Zheng (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect	Events 0 0 0 0 0 0 0 0 1 1 0 16 2 2 5.66, df 2 2 5.35 0 1 10 16 2 2 5.35 0 1 10 16 2 5 5.35 17 10 16 16 16 16 16 16 16 17 17 16 16 16 16 16 17 17 17 17 17 17 17 17 17 17 17 17 17	Tota 6 19 26 1 (P = Total 388 53 42 195 52 380 = 4 (P < 0 + (P < 0) hine	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² Contro	Total 66 13 53 41 65 52 249 2 49	7 100.1 5 2 100.0 2 100.0 2 100.0 3 2 100.0 5 6.0% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.14 [0.01, 2 0 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0 0.40 [0.00, 0.61] 0 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58] 0 0.37 [0.25, 0.53] Relative Risk Relative Risk	S% CI M-H, Random, 95% CI 2.67] Image: Control for the system of the system
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect '. Injection pain Study or Subgroup Liu 2023 Liu 2022 Zhan 2022 Zhan 2022 Zheng (a) 2023 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect S. Cough Study or Subgroup	Events 0 0 0 0 0 0 0 0 0 0 0 0 0	Tota 6 19 26 1 (P = 7 7 0 1 (P = 380 380 380 (P < 0 (P < 0 (P < 0 10) 10 10 10 10 10 10 10 10 10 10 10 10 10	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events	Tota 6 6 13 388 53 41 65 52 249 = 299 1 Fotal	7 100. 5 2 100.0 Weight 17.3% 17.3% 17.3% 56.0% 100.0% % Weight	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.16 [0.00, 0.61] 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 1 0.38 [0.25, 0.53] 0.37 [0.25, 0.53] 0.37 [0.25, 0.53]	6% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Lu 2022 Xu (a) 2022 Zhang (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect . Cough Study or Subgroup Feng (b) 2022	Events 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 6 19 26 1 (P = <u>Total</u> 38 380 = 4 (P < 0 (P < 0 10 52 380 10 55 22 380 10 55 22 380 10 52 380 10 10 10 10 10 10 10 10 10 10 10 10 10	al Events 8 3 5 0 3 3 0.19) Contro Events 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 1 7	Total 6 13 52 249 52 249 52 249 52 1 52 249 52 249 52 249 52 249 52 249 52 249 52 249 52 52 52 52 52 52 52 52 52 52 52 52 52	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.14 [0.01, 2 0 0.14 [0.01, 2 0 0.14 [0.00, 0.1] 0.04 [0.00, 0.61] 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.53] 6 0.37 [0.25, 0.53] 6 0.37 [0.25, 0.53] Relative Risk M-H, Random, 95% CI 1.14 [0.46, 2.85] 1.14 [0.46, 2.85]	S% CI M-H, Random, 95% CI 2.67]
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022 Zhan 2022 Zhan 2022 Zhang (a) 2023 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect . Cough Study or Subgroup Feng (b) 2022 Lin 2023	Events 0 0 0 0 0 0 0 0 0 1 10 16 2 5 5 0 1 10 16 2 5 5 5 0 1 10 16 2 5 5 5 0 1 10 16 8 2 5 5 5 0 1 10 16 16 16 16 16 16 16 16 16 16 16 16 16	Tota 6 19 26 1 (P = mine Total 38 42 195 380 = 4 (P (P < 0	al Events 8 3 5 0 3 3 0.19) Contro Events 73 = 0.23); l ² 0.0001) Contro Events 7 2	Tota 6 6 13 38 53 41 65 52 249 = 299 = 299 1 fotal 40 22	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 56.0% 100.0% % Weight 23.1% 11.7%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.49 [0.05, 5.18] 0 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58] 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] Relative Risk M-H, Random, 95% CI 1.14 [0.46, 2.85] 1.50 [0.28, 8.12]	5% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022 Zhan 2022 Zhan 2022 Zhang (a) 2023 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect Cough Study or Subgroup Feng (b) 2022 Lin 2023	Events 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 4 4 4 4 4 4 4 4 4 4 4 4 4	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28	Total 6 6 6 13 3 70tal 38 53 41 65 52 249 3 i 1 fotal 40 40 22 42 42	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 56.0% 100.0% % Weight 23.1% 11.7% 27.6%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0.04 [0.00, 0.61] 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.53] 3 0.37 [0.25, 0.53] 4 0.49 [0.05, 5.18] 1.14 [0.46, 2.85] 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.25 [0.12, 0.51]	5% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Xu (a) 2022 Zhan 2022 Zhan 2022 Zheng (a) 2023 Total events Heterogeneity: Chi ² = Test for overall effect . Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022	Events 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 4 4 4 4 4 4 4 4 4 4 4 4 4	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28	Tota 6 6 13 38 53 41 65 52 249 249 2 249 2 249 2 42 65	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 56.0% 100.0% % Weight 23.1% 11.7% 27.6%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0.04 [0.00, 0.61] 0.49 [0.05, 5.18] 1.11 [0.32, 3.91] 0.38 [0.25, 0.53] 3 0.37 [0.25, 0.53] 4 0.49 [0.05, 5.18] 1.14 [0.46, 2.85] 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.25 [0.12, 0.51]	S% CI M-H, Random, 95% CI 2.67] Image: Control for the system of the system
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect 7. Injection pain Study or Subgroup Liu 2023 Luu 2022 Xu (a) 2022 Zhan 2022 Zhan 2022 Zheng (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect 8. Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022 Total (95% CI)	Events 0 0 0 0 0 0 0 0 0 0 0 0 0	Tota 6 19 26 10 701 380 380 9 10 10 10 11 10 11 12 12 12 12 12 12	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28	Tota 6 6 13 38 53 41 65 52 249 249 2 249 2 249 2 42 65	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 8.0% 56.0% 100.0% % Weight 23.1% 11.7% 27.6% 37.6%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0 0.38 [0.15, 0.97] 0.04 [0.00, 0.61] 0.04 [0.00, 0.61] 5 0.38 [0.25, 0.58] 1.11 [0.32, 3.91] 0.38 [0.25, 0.58] 5 0.37 [0.25, 0.53] 6 0.37 [0.25, 0.53] 7 [0.46, 2.85] 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.25 [0.12, 0.51] 0.74 [0.60, 0.91]	S% CI M-H, Random, 95% CI 2.67] Image: Control for the system of the system
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022 Zhan 2022 Zhang (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect B. Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022 Total (95% CI) Total events	Events 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 16 2 5.66, df 5 5.2 5.35 2 5.66, df 5 2 5.35 2 5.45, df 1 10 0 16 10 10 10 10 10 10 10 10 10 10 10 10 10	Total 6 19 26 19 26 19 26 19 52 380 = 4 (P (P < 0 (P < 0 0 22 195 299	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² 0.00001) Contro Events 1 7 2 8 46 83	Total 6 13 53 41 65 52 249 = 29 1 1 1 65 169	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 2 100.0 5 2 100.0 5 6.0% 5 6.0% 100.0% 3 7.6% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.14 [0.01, 2 1 0.14 [0.01, 2 0 0.4 [0.00, 0.61] 1 0.12, 3.91] 1 0.38 [0.25, 0.53] 1 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] 1 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.74 [0.60, 0.91] 0.66 [0.33, 1.31]	5% Cl M-H, Random, 95% Cl 2.67] Image: Cl 0.01 0.1 1 0.01 0.1 1 0.01 0.1 10 Relative Risk M-H, Fixed, 95% Cl Image: Control Image: Control 0.01 0.1 1 Image: Control Image: Control Image: Control Image: Co
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect T. Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhan 2022 Zhan 2022 Zhan 2022 Zhan 2022 Cough (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect S. Cough Study or Subgroup Feng (b) 2022 Lin 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Tau ² =	Events 0 0 0 0 0 0 0 0 0 0 0 1 10 16 2 5.66, df 2 2 5.35 2 5.35 2 5.35 2 5.35 102 2 5.35 2 5.35 2 5.35 2 5.35 2 5 5 0 0 1 10 10 10 10 10 10 10 10 10 10 10	Tota 6 1 (P = 7 7 1 (P = 7 7 380 380 = 4 (P (P < 0 7 10 2 380 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 10 5 2 10 19 2 6 19 2 19 2	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28 46 83 .85, df = 3	Total 6 13 53 41 65 52 249 = 29 1 1 1 65 169	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 2 100.0 5 2 100.0 5 6.0% 5 6.0% 100.0% 3 7.6% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.14 [0.01, 2 1 0.14 [0.01, 2 0 0.4 [0.00, 0.61] 1 0.12, 3.91] 1 0.38 [0.25, 0.53] 1 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] 1 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.74 [0.60, 0.91] 0.66 [0.33, 1.31]	5% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhang (a) 2023 Total events Heterogeneity: Chi ² = Total vents Heterogeneity: Chi ² = Total vents Heterogeneity: Chi ² = S. Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022 Total events Heterogeneity: Tau ² =	Events 0 0 0 0 0 0 0 0 0 0 0 1 10 16 2 5.66, df 2 2 5.35 2 5.35 2 5.35 2 5.35 102 2 5.35 2 5.35 2 5.35 2 5.35 2 5 5 0 0 1 10 10 10 10 10 10 10 10 10 10 10	Tota 6 1 (P = 7 7 1 (P = 7 7 380 380 = 4 (P (P < 0 7 10 2 380 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 10 5 2 10 19 2 6 19 2 19 2	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28 46 83 .85, df = 3	Total 6 13 53 41 65 52 249 = 29 1 1 1 65 169	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 2 100.0 5 2 100.0 5 6.0% 5 6.0% 100.0% 3 7.6% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.14 [0.01, 2 1 0.14 [0.01, 2 0 0.4 [0.00, 0.61] 1 0.12, 3.91] 1 0.38 [0.25, 0.53] 1 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] 1 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.74 [0.60, 0.91] 0.66 [0.33, 1.31]	5% Cl M-H, Random, 95% Cl 2.67] Image: Cl 0.01 0.1 1 0.01 0.1 1 0.01 0.1 10 Relative Risk M-H, Fixed, 95% Cl Image: Control Image: Control 0.01 0.1 1 Image: Control Image: Control Image: Control Image: Co
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect Injection pain Study or Subgroup Liu 2023 Lu 2022 Zhan 2022 Zhan 2022 Zhang (a) 2023 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect B. Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022 Total (95% CI) Total events	Events 0 0 0 0 0 0 0 0 0 0 0 1 10 16 2 5.66, df 2 2 5.35 2 5.35 2 5.35 2 5.35 102 2 5.35 2 5.35 2 5.35 2 5.35 2 5 5 0 0 1 10 10 10 10 10 10 10 10 10 10 10	Tota 6 1 (P = 7 7 1 (P = 7 7 380 380 = 4 (P (P < 0 7 10 2 380 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 10 5 2 10 19 2 6 19 2 19 2	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28 46 83 .85, df = 3	Total 6 13 53 41 65 52 249 = 29 1 1 1 65 169	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 2 100.0 5 2 100.0 5 6.0% 5 6.0% 100.0% 3 7.6% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.14 [0.01, 2 1 0.14 [0.01, 2 0 0.4 [0.00, 0.61] 1 0.12, 3.91] 1 0.38 [0.25, 0.53] 1 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] 1 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.74 [0.60, 0.91] 0.66 [0.33, 1.31]	5% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhang (a) 2023 Total events Heterogeneity: Chi ² = Total vents Heterogeneity: Chi ² = Total vents Heterogeneity: Chi ² = S. Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022 Total events Heterogeneity: Tau ² =	Events 0 0 0 0 0 0 0 0 0 0 0 1 10 16 2 5.66, df 2 2 5.35 2 5.35 2 5.35 2 5.35 102 2 5.35 2 5.35 2 5.35 2 5.35 2 5 5 0 0 1 10 10 10 10 10 10 10 10 10 10 10	Tota 6 1 (P = 7 7 1 (P = 7 7 380 380 = 4 (P (P < 0 7 10 2 380 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 10 5 2 10 19 2 6 19 2 19 2	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28 46 83 .85, df = 3	Total 6 13 53 41 65 52 249 = 29 1 1 1 65 169	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 2 100.0 5 2 100.0 5 6.0% 5 6.0% 100.0% 3 7.6% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.14 [0.01, 2 1 0.14 [0.01, 2 0 0.4 [0.00, 0.61] 1 0.12, 3.91] 1 0.38 [0.25, 0.53] 1 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] 1 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.74 [0.60, 0.91] 0.66 [0.33, 1.31]	5% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second
Cui 2023 Zhan 2022 Total (95% CI) Total events Heterogeneity: Not a Test for overall effect . Injection pain Study or Subgroup Liu 2023 Liu 2022 Xu (a) 2022 Zhang (a) 2023 Total events Heterogeneity: Chi ² = Total events Heterogeneity: Chi ² = Cough Study or Subgroup Feng (b) 2022 Lin 2023 Nie 2023 Zhan 2022 Total events Heterogeneity: Tau ² =	Events 0 0 0 0 0 0 0 0 0 0 0 1 10 16 2 5.66, df 2 2 5.35 2 5.35 2 5.35 2 5.35 102 2 5.35 2 5.35 2 5.35 2 5.35 2 5 5 0 0 1 10 10 10 10 10 10 10 10 10 10 10	Tota 6 1 (P = 7 7 1 (P = 7 7 380 380 = 4 (P (P < 0 7 10 2 380 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 10 5 2 10 19 2 6 19 2 19 2	al Events 8 3 5 0 3 3 0.19) Contro Events 13 13 2 3 42 73 = 0.23); l ² .00001) Contro Events 7 2 28 46 83 .85, df = 3	Total 6 13 53 41 65 52 249 = 29 1 1 1 65 169	7 100.5 2 100.0 2 100.0 2 100.0 2 100.0 3 2 100.0 3 2 100.0 5 2 100.0 5 6.0% 5 6.0% 100.0% 3 7.6% 100.0%	Int M-H, Random, 95 0% 0.14 [0.01, 2 Not estim Not estim 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 0% 0.14 [0.01, 2 1 0.14 [0.01, 2 1 0.14 [0.01, 2 0 0.4 [0.00, 0.61] 1 0.12, 3.91] 1 0.38 [0.25, 0.53] 1 0.37 [0.25, 0.53] 0.37 [0.25, 0.53] 1 1.14 [0.46, 2.85] 1.50 [0.28, 8.12] 0.74 [0.60, 0.91] 0.66 [0.33, 1.31]	5% Cl M-H, Random, 95% Cl 2.67] Image: Control for the second

found in oxygen desaturation (RR = 0.60, 95%CI = [0.35, 1.02], p = 0.06); cough and body movement (RR = 0.85, 95%CI = [0.41, 1.76], p = 0.66); nausea and/or vomiting (RR = 0.64, 95%CI = [0.25, 1.61], p = 0.34); emergence delirium (RR = 1.63, 95%CI = [0.06, 44.29], p =

0.77); awakening time (SMD = -0.79, 95%CI = [-2.71, 1.14], p = 0.42); and recovery time (SMD = 0.66, 95%CI = [-0.15, 1.47], p = 0.11) compared with drug regimens of the control group (Figures 3A,B; Table 3).

FIGURE 2 (Continued).

C 9. Body movement

	Esketar	mine	Cont	rol		Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Chen 2022	14	133	12	45	14.9%	0.39 [0.20, 0.79]	
Liu 2023	21	38	30	38	23.6%	0.70 [0.50, 0.97]	
Xin 2024	6	50	16	100	11.6%	0.75 [0.31, 1.80]	
Zhan 2022	136	195	54	65	27.3%	0.84 [0.73, 0.97]	-
Zheng (a) 2023	19	52	48	52	22.6%	0.40 [0.27, 0.57]	
Total (95% CI)		468		300	100.0%	0.60 [0.41, 0.88]	•
Total events	196		160				
Heterogeneity: Tau ² =	= 0.14; Ch	$i^2 = 20$.94, df =	4 (P =	0.0003)	$l^2 = 81\%$	
Test for overall effect	: Z = 2.60	(P = 0)	.009)				0.05 0.2 i 5 20 Favours [experimental] Favours [control]

10. Nausea and/or vomiting

	Esketai		Conti			Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Chen 2022	10	133	1	45	1.9%	3.38 [0.45, 25.70]	
Cui 2023	8	68	5	67	6.5%	1.58 [0.54, 4.57]	
Eberl 2020	0	83	0	79		Not estimable	
Feng (a) 2022	1	75	2	25	3.9%	0.17 [0.02, 1.76]	
Feng (b) 2022	5	40	6	40	7.8%	0.83 [0.28, 2.51]	
Lin 2023	4	22	6	22	7.8%	0.67 [0.22, 2.04]	
Liu 2023	0	38	0	38		Not estimable	
Lu 2022	3	53	6	53	7.8%	0.50 [0.13, 1.90]	
Ma 2024	1	81	0	79	0.7%	2.93 [0.12, 70.79]	
Nie 2023	14	42	26	42	33.7%	0.54 [0.33, 0.88]	
Si 2024	6	60	7	60	9.1%	0.86 [0.31, 2.40]	
Song 2023	6	331	6	329	7.8%	0.99 [0.32, 3.05]	
Wang 2019	3	16	6	16	7.8%	0.50 [0.15, 1.66]	
Xu (a) 2022	2	42	2	41	2.6%	0.98 [0.14, 6.61]	
Yang 2022	0	60	1	30	2.6%	0.17 [0.01, 4.04]	· · · · · · · · · · · · · · · · · · ·
Zhan 2022	0	195	0	65		Not estimable	
Zheng (a) 2023	0	52	0	52		Not estimable	
Total (95% CI)		1391		1083	100.0%	0.76 [0.56, 1.02]	•
Total events	63		74				
Heterogeneity: Chi ² =	10.16, d	f = 12 (P = 0.60); $ ^2 =$	0%		0.01 0.1 1 10 100
Test for overall effect:							0.01 0.1 1 10 100 Favours [experimental] Favours [control]

11. Propofol consumption

	esk	etamin	e	0	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Chen 2023	207	60	75	187	46	25	20.1%	0.35 [-0.11, 0.80]	+
Feng (a) 2022	146.13	58.03	75	277.4	49	25	19.9%	-2.33 [-2.89, -1.77]	+
Liu 2023	101.64	32.64	38	129.55	36.34	38	20.1%	-0.80 [-1.27, -0.33]	+
Nie 2023	125	35.3	42	144.4	38.2	42	20.2%	-0.52 [-0.96, -0.09]	+
Zheng (a) 2023	201.3	16.6	52	274.4	22.6	52	19.7%	-3.66 [-4.30, -3.02]	+
Total (95% CI)			282			182	100.0%	-1.38 [-2.64, -0.11]	•
Heterogeneity: Tau ² =				f = 4 (P <	< 0.000	01); l ² :	= 97%		-10 -5 0 5 10
Test for overall effect	Z = 2.14	(P = 0.	03)						Favours [experimental] Favours [control]

12. Psychiatric symptoms

	Esketar	mine	Contr	ol		Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Chen 2022	6	133	0	45	2.8%	4.46 [0.26, 77.68]	
Cui 2023	1	68	0	67	1.9%	2.96 [0.12, 71.31]	
Feng (b) 2022	0	40	0	40		Not estimable	
Liu 2023	18	38	11	38	41.9%	1.64 [0.90, 2.98]	+
Nie 2023	0	42	0	42		Not estimable	
Si 2024	10	60	5	60	19.0%	2.00 [0.73, 5.50]	
Song 2023	4	331	1	329	3.8%	3.98 [0.45, 35.38]	
Wang 2019	1	16	2	16	7.6%	0.50 [0.05, 4.98]	· · ·
Xin 2024	28	50	5	100	12.7%	11.20 [4.60, 27.24]	
Xu (a) 2022	2	42	0	41	1.9%	4.88 [0.24, 98.73]	
Yang 2022	2	60	0	30	2.5%	2.54 [0.13, 51.31]	
Zhan 2022	4	195	1	65	5.7%	1.33 [0.15, 11.72]	
Zheng (a) 2023	0	52	0	52		Not estimable	
Total (95% CI)		1127		925	100.0%	3.10 [2.11, 4.54]	•
Total events	76		25				
Heterogeneity: Chi ² =		f = 9 (P)		$ ^2 = 4$	5%		the state of the state
Test for overall effect							0.01 0.1 1 10 100 Favours [experimental] Favours [control]
							Favours (experimental) Favours (control)

Because only one study used the esketamine-midazolam combination, which reported data on nausea and/or vomiting and body movement, we did not conduct a subgroup analysis of the esketamine regimens in children (Pees et al., 2003). After eliminating this single esketamine-midazolam study, the pooled results of children was not changed (data was not shown). Esketamine dose subgroup analysis showed a significant decrease in the risk of hypotension (RR = 0.33,

D

13. Dizziness

	Esketar	nine	e Control			Relative Risk	Relative Risk
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Feng (a) 2022	7	75	1	25	2.8%	2.33 [0.30, 18.05]	
Liu 2023	24	38	18	38	22.2%	1.33 [0.88, 2.02]	
Nie 2023	13	42	15	42	16.6%	0.87 [0.47, 1.59]	
Song 2023	73	331	69	329	26.1%	1.05 [0.79, 1.41]	+
Wang 2019	5	16	9	16	11.5%	0.56 [0.24, 1.29]	
Xin 2024	11	50	4	100	8.1%	5.50 [1.84, 16.41]	
Zhan 2022	26	195	7	65	12.6%	1.24 [0.56, 2.72]	
Zheng (a) 2023	0	52	0	52		Not estimable	
Total (95% CI)		799		667	100.0%	1.19 [0.83, 1.71]	+
Total events	159		123				
Heterogeneity: Tau ² =	0.11; Ch	$i^2 = 12$.93, df =	6 (P =	0.04); I ²	= 54%	
Test for overall effect							0.01 0.1 1 10 100 Esketamine Control

14. Awakening time

	Expe	rimen	ntal Control				:	Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
Chen 2023	11.07	5.43	75	9.1	4.3	25	16.5%	0.38 [-0.08, 0.83]			
Feng (a) 2022	11.82	3.6	75	10.9	2.6	25	16.5%	0.27 [-0.18, 0.72]	+		
Lu 2022	11.12	5.31	53	13.21	5.62	53	16.8%	-0.38 [-0.76, 0.00]			
Nie 2023	3.4	1.3	42	3.1	1.3	42	16.6%	0.23 [-0.20, 0.66]	- -		
Xin 2024	15.55	5.09	50	9.65	3.62	100	16.9%	1.41 [1.03, 1.79]			
Zheng (a) 2023	4.8	1.3	52	6.2	1.1	52	16.7%	-1.15 [-1.57, -0.74]	_ -		
Total (95% CI)			347			297	100.0%	0.13 [-0.59, 0.85]			
Heterogeneity: Tau ² =	0.76; C	:hi ² = 8	89.45,								
Test for overall effect	Z = 0.3	4 (P =	0.73)						Favours [experimental] Favours [control]		

15. Recovery time

	Expe	rimen	tal	C	Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Chen 2022	10.38	2.38	133	10.11	1.97	45	28.2%	0.12 [-0.22, 0.46]	
Lin 2023	6.5	2.2	22	9.05	2.72	22	20.7%	-1.01 [-1.64, -0.38]	
Liu 2023	3.71	2.18	38	3	1.64	38	25.3%	0.36 [-0.09, 0.82]	
Xu (a) 2022	8.8	3.2	42	9.2	3.5	41	25.9%	-0.12 [-0.55, 0.31]	
Total (95% CI)			235			146	100.0%	-0.11 [-0.58, 0.35]	-
Heterogeneity: Tau ² =	0.17; C	:hi ² = 1	13.09,						
Test for overall effect:	Z = 0.4	8 (P =	0.63)						Favours [experimental] Favours [control]

16. Orientation recovery time

	Experimental			c	ontrol		1	Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Chen 2022	13.42	3.28	133	12.93	1.84	45	23.6%	0.16 [-0.18, 0.50]			
Lu 2022	23.98	6.22	53	26.32	5.96	53	18.3%	-0.38 [-0.77, 0.00]			
Wang 2019	11.5	14.07	16	17	17.04	16	5.5%	-0.34 [-1.04, 0.36]			
Zhan 2022	14.47	4.028	195	14.26	3.989	65	34.3%	0.05 [-0.23, 0.33]			
Zheng (a) 2023	13.9	2.4	52	14.1	2.1	52	18.3%	-0.09 [-0.47, 0.30]			
Total (95% CI)			449			231	100.0%	-0.05 [-0.21, 0.12]	•		
Heterogeneity: Chi ² =	5.60, df	f = 4 (P)	= 0.23); $I^2 = 2$	9%						
Test for overall effect	Z = 0.5	8 (P = 0)	0.56)						Favours [experimental] Favours [control]		

FIGURE 2

(Continued). (A) Forest plots of adults (1. Oxygen desaturation, 2. Hypotension, and 3. Bradycardia). (B) Forest plots of adults (4. Hypertension, 5. Tachycardia, 6. Arrhythmia, 7. Injection pain, and 8. Cough). (C) Forest plots of adults (9. Body movement, 10. Nausea and/or vomiting, 11. Propofol consumption, and 12. Psychiatric symptoms). (D) Forest plots of adults (13. Dizziness, 14. Awakening time, 15. Recovery time, and 16. Orientation recovery time).

95%CI = [0.15, 0.75], p = 0.008) and dizziness (RR = 2.36, 95%) CI = [1.34, 4.18], p = 0.003) in the esketamine>0.5 mg/kg subgroup, but a non-significant difference in the esketamine ≤ 0.5 mg/kg subgroup (*hypotension*: RR = 0.73, 95%CI = [0.45, 1.18], p = 0.19, and test for subgroup differences p = 0.11; *dizziness*: RR = 1.72, 95%CI = [0.98,

TABLE 3 Results of meta-analysis in adults and children.

Outcome indicators	Studies	No.	RR or SMD [95%]	<i>p</i> -value	²
Adults					
Oxygen desaturation	17 Chen et al. (2022); Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Feng et al. (2022); Lin et al. (2023); Liu et al. (2023); Lu et al. (2022); Ma et al. (2024); Nie et al. (2023); Si et al. (2024); Song et al. (2023); Xin et al. (2024); Xu et al. (2022); Zhan et al. (2022); Zheng et al. (2023)	2,602	0.49 [0.34, 0.70]	<i>p</i> < 0.0001	54%
Hypotension	16 Chen et al. (2022); Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Feng et al. (2022); Lin et al. (2023); Liu et al. (2023); Lu et al. (2022); Ma et al. (2024); Si et al. (2024); Song et al. (2023); Xin et al. (2024); Xu et al. (2022); Yang et al. (2022); Zhan et al. (2022); Zheng et al. (2023)	2,528	0.38 [0.31, 0.46]	<i>p</i> < 0.00001	39%
Bradycardia	11 Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Lin et al. (2023); Liu et al. (2023); Lu et al. (2022); Ma et al. (2024); Xin et al. (2024); Xu et al. (2022); Yang et al. (2022); Zheng et al. (2022)	1,210	0.23 [0.12, 0.43]	<i>p</i> < 0.00001	10%
Hypertension	10 Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Lin et al. (2023); Liu et al. (2023); Ma et al. (2024); Wang et al. (2019); Xin et al. (2024); Xu et al. (2022); Zhan et al. (2022)	1,202	1.75 [0.75, 4.06]	<i>p</i> = 0.19	56%
Tachycardia	7 Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Liu et al. (2023); Ma et al. (2024); Xin et al. (2024); Xu et al. (2022)	866	1.72 [0.76, 3.93]	<i>p</i> = 0.20	64%
Arrhythmia	2 Cui et al. (2023); Zhan et al. (2022)	395	0.14 [0.01, 2.67]	<i>p</i> = 0.19	-
Injection pain	5 Liu et al. (2023); Lu et al. (2022); Xu et al. (2022); Zhan et al. (2022); Zhan et al. (2022)	629	0.37 [0.25, 0.53]	<i>p</i> < 0.00001	29%
Cough	4 Feng et al. (2022); Lin et al. (2023); Nie et al. (2023); Zhan et al. (2022)	468	0.66 [0.33, 1.31]	<i>p</i> = 0.24	72%
Body movement	5 Chen et al. (2022); Liu et al. (2023); Xin et al. (2024); Zhan et al. (2022); Zheng et al. (2022)	768	0.60 [0.41, 0.88]	<i>p</i> = 0.009	81%
Nausea and/or vomiting	17 Chen et al. (2022); Cui et al. (2023); Eberl et al. (2020); Feng et al., 2022; Lin et al. (2023); Liu et al. (2023); Lu et al. (2022); Ma et al. (2024); Nie et al. (2023); Si et al. (2024); Song et al. (2023); Wang et al. (2019); Xu et al. (2022); Yang et al. (2022); Zhan et al. (2022); Zheng et al. (2023)	2,474	0.76 [0.56, 1.02]	<i>p</i> = 0.07	0%
Propofol consumption	5 Chen et al. (2023); Feng et al. (2022); Liu et al. (2023); Nie et al. (2023); Zheng et al. (2023)	464	-1.38 [-2.64, -0.11]	<i>p</i> = 0.03	97%
Psychiatric symptoms	13 Chen et al. (2022); Cui et al. (2023); Feng et al. (2022); Liu et al. (2023); Nie et al. (2023); Si et al. (2024); Song et al. (2023); Wang et al. (2019); Xin et al. (2024); Xu et al. (2022); Yang et al. (2022); Zhan et al. (2022); Zheng et al. (2022)	2052	3.10 [2.11, 4.54]	<i>p</i> < 0.00001	45%
Dizziness	8 Feng et al. (2022); Liu et al. (2023); Nie et al. (2023); Song et al. (2023); Wang et al. (2019); Xin et al. (2024); Zhan et al. (2022); Zheng et al. (2022)	1,466	1.19 [0.83, 1.71]	<i>p</i> = 0.34	54%
Awakening time	6 Chen et al. (2023); Feng et al. (2022); Lu et al. (2022); Nie et al. (2023); Xin et al. (2024); Zheng et al. (2022)	644	0.13 [-0.59, 0.85]	<i>p</i> = 0.73	94%
Recovery time	4 Chen et al. (2022); Lin et al. (2023); Liu et al. (2023); Xu et al. (2022)	381	-0.11 [-0.58, 0.35]	<i>p</i> = 0.63	77%
Orientation recovery time	5 Chen et al. (2022); Lu et al. (2022); Wang et al. (2019); Zhan et al. (2022); Zheng et al. (2022)	680	-0.05 [-0.21, 0.12]	<i>p</i> = 0.56	29%
Children					
Oxygen desaturation	5 Wang et al. (2022); Xu et al. (2022); Zheng et al. (2022); Zheng et al. (2022); Zhong et al. (2023)	594	0.60 [0.35, 1.02]	<i>p</i> = 0.06	47%
Hypotension	3 Wang et al. (2022); Xu et al. (2022); Zheng et al. (2022)	322	0.59 [0.37, 0.95]	<i>p</i> = 0.03	0%
Cough and body movement	3 Pees et al. (2003); Wang et al. (2022); Xu et al. (2022)	306	0.85 [0.41, 1.76]	<i>p</i> = 0.66	0%

(Continued on following page)

TABLE 3 (Continued) Results of meta-analysis in adults and children.

Outcome indicators	Studies	No.	RR or SMD [95%]	<i>p</i> -value	²
Nausea and/or vomiting	6 Pees et al. (2003); Wang et al. (2022); Xu et al. (2022); Zheng et al. (2022); Zheng et al. (2022); Zhong et al. (2023)	670	0.64 [0.25, 1.61]	<i>p</i> = 0.34	0%
Emergence delirium	3 Xu et al. (2022); Zheng et al. (2022); Zhong et al. (2023)	275	1.63 [0.06, 44.29]	<i>p</i> = 0.77	81%
Visual disturbance	3 Wang et al. (2022); Zheng et al. (2022); Zheng et al. (2022)	411	6.62 [2.18, 20.13]	<i>p</i> = 0.0009	0%
Dizziness	4 Wang et al. (2022); Zheng et al. (2022); Zheng et al. (2022); Zhong et al. (2023)	483	1.99 [1.17, 3,37]	<i>p</i> = 0.01	0%
Awakening time	2 Xu et al. (2022); Zheng et al. (2022)	311	-0.79 [-2.71, 1.14]	<i>p</i> = 0.42	98%
Recovery time	2 Wang et al. (2022); Zhong et al. (2023)	191	0.66 [-0.15, 1.47]	p = 0.11	84%

TABLE 4 Adults: esketamine drug regimens subgroup analysis (combination of esketamine with propofol versus other drugs).

Outcome indicators	Studies	RR [95%]	<i>p</i> -value	²
Oxygen desaturation				
esketamine + propofol	15 Chen et al. (2022); Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Feng et al. (2022); Liu et al. (2023); Ma et al. (2024); Nie et al. (2023); Si et al. (2024); Song et al. (2023); Xin et al. (2024); Xu et al. (2022); Zhan et al. (2022); Zheng et al. (2023)	0.51 [0.35, 0.74]	<i>p</i> = 0.0003	57%
esketamine + non-propofol	2 Lin et al. (2023); Lu et al. (2022)	0.23 [0.05, 1.06]	<i>p</i> = 0.06	0%
Hypotension				
esketamine + propofol	14 Chen et al. (2022); Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Feng et al. (2022); Liu et al. (2023); Ma et al. (2024); Si et al. (2024); Song et al. (2023); Xin et al. (2024); Xu et al. (2022); Yang et al. (2022); Zhan et al. (2022); Zheng (a) et al., 2023	0.38 [0.31, 0.46]	<i>p</i> < 0.00001	45%
esketamine + non-propofol	2 Lin et al. (2023); Lu et al. (2022)	0.26 [0.07, 1.00]	<i>p</i> = 0.05	0%
Bradycardia				
esketamine + propofol	9 Chen et al. (2023); Cui et al. (2023); Eberl et al. (2020); Liu et al. (2023); Ma et al. (2024); Xin et al. (2024); Xu et al. (2022); Yang et al. (2022); Zheng et al. (2023)	0.24 [0.12, 0.47]	<i>p</i> < 0.0001	17%
esketamine + non-propofol	2 Lin et al. (2023); Lu et al. (2022)	0.14 [0.02, 1.12]	<i>p</i> = 0.06	-
Nausea and/or vomiting				
esketamine + propofol	15 Chen et al. (2022); Cui et al. (2023); Eberl et al. (2020); Feng et al. (2022); Feng et al. (2022); Liu et al. (2023); Ma et al. (2024); Nie et al. (2023); Si et al. (2024); Song et al. (2023); Wang et al. (2019); Xu et al. (2022); Yang et al. (2022); Zhan et al. (2022); Zheng et al. (2023)	0.79 [0.57, 1.09]	<i>p</i> = 0.15	0%
esketamine + non-propofol	2 Lin et al. (2023); Lu et al. (2022)	0.58 [0.25, 1.38]	<i>p</i> = 0.22	0%

3.02], p = 0.06, and test for subgroup differences p = 0.44). No significant difference was found in oxygen desaturation, nausea and/or vomiting, and visual disturbance in the esketamine dose subgroup analyses (Table 5).

3.4 Sensitivity analysis

We conducted a sensitivity analysis of the primary outcomes (cardiorespiratory adverse events) by eliminating one included study each time. There was no significant difference in the sensitivity analysis in adults. In children, the pooled results of oxygen desaturation were altered after eliminating the study by Zheng (b) 2023 (Zheng (b) et al., 2023), and that of hypotension was altered after eliminating the studies by Wang et al., 2022; Zheng et al. 2022; Wang et al., 2022; Zheng et al., 2022). Due to concerns regarding a high risk of bias, we performed a sensitivity analysis that excluded the study by Pees et al. (Pees et al., 2003). After this exclusion, the pooled results of cough and body movement, and nausea and/or vomiting in children remained consistent.

3.5 Publication bias analysis

We assessed publication bias for six indicators, each reported in no less than 10 studies, including oxygen desaturation, hypotension,



bradycardia, hypertension, nausea and/or vomiting, and psychiatric symptoms, and the results of this analysis are shown in Supplementary Material S3. However, the symmetry of the four funnel plots for three of these indicators, such as oxygen desaturation, hypotension, hypertension and psychiatric symptoms, was less than ideal, suggesting a possible publication bias.

В

7. Dizziness

7. Dizziness			-						
c	Esketar		Cont			Relative Risl		Relative Risk	
Study or Subgroup	Events				-	M-H, Fixed, 95		M-H, Fixed, 95% CI	
Wang 2022	47	89	8	30	68.5%				
Zheng (b) 2023	6	100	1	100	5.7%		-		_
Zheng 2022	10	69	3	23	25.8%				
Zhong 2023	0	36	0	36		Not estim	able		
Total (95% CI)		294		189	100.0%	1.99 [1.17, 3	.37]	◆	
Total events	63		12						
Heterogeneity: Chi ² =	= 1.97, df =	= 2 (P =	0.37);	$^{2} = 0\%$			0.01	0.1 1 10	100
Test for overall effect	t: Z = 2.54	(P = 0.	01)				0.01	Favours [experimental] Favours [control]	100
								arours (experimental) rarours (control)	
8. Awakening time	e								
	Experim	ental	Co	ntrol		Std. Mean Di	ference	Std. Mean Difference	
Study or Subgroup	Mean S	D Tota	Mean	SD TO	otal Wei	ght IV, Random	, 95% CI	IV, Random, 95% CI	
Xu (b) 2022	11.2 5.	1 56	20.6	5.4	55 49	.6% -1.78 [-2.2]	2, -1.34]		
Zheng (b) 2023	15.7 7.	9 100	14.3	6.9	100 50	.4% 0.19 [-0.0	9, 0.47]	₽ -	
Total (95% CI)		156			155 100	.0% -0.79 [-2.	71 1 1 41		
	1 00. Chi2						1, 1.14]		
Heterogeneity: Tau ² = Test for overall effect:				(P < 0.0)0001); F	= 98%		-4 -2 0 2	4
rescior overall effect.	2 - 0.00 (r	- 0.42	,					Favours [experimental] Favours [control]	
9. Recovery time									
. need very time	Experim	ental	c	Control		Std. Mean	Difference	Std. Mean Difference	
Study or Subgroup		D Tota			Total V	Veight IV, Rando		IV, Random, 95% CI	
Wang 2022	32.91 16.	03 8	9 28.7	15.66	30	51.4% 0.26 [-	0.15, 0.68]	+	
Zhong 2023	15.06 1.	65 3	5 13.01	2.05	36	48.6% 1.09 [0.59, 1.59]		
Total (95% CI)		12	5		66 1	00.0% 0.66 [-	0.15, 1.47]	-	
Heterogeneity: Tau ² =	0.29; Chi ² =	6.27, d	f = 1 (P =	= 0.01);	$l^2 = 84\%$				1
Test for overall effect: 2	Z = 1.61 (P)	= 0.11)						Favours [experimental] Favours [control]	4
								ratears (experimental) ratears [control]	
GURE 3									
	plots of chi	ldren (1	Oxygen	desatu	iration, 2.	Hypotension, 3.	Cough and	l body movement, 4. Nausea and/or vomiting	g, 5.
nergence delirium an	d 6 Visual	disturba	nce) (B)	Forest	nlots of	children (7. Dizzi	ness 8 Aw	akening time, and 9. Recovery time).	

4 Discussion

In this study, we assessed the safety and efficacy of intravenous esketamine as an adjuvant for sedation or analgesia in adults and children undergoing surgical procedures outside the operating room. The unique pharmacodynamics of esketamine (such as dissociative anesthetic property, sympathetic excitatory activity, and local anesthetic action) and the synergistic effect of drug combinations were considered to account for the reduced risk of hypotension, bradycardia, oxygen desaturation, injection pain, and body movement and decreased propofol consumption (Li et al., 2022; Xu et al., 2022; Zhan et al., 2022; Zheng (a) et al., 2023).

Three recent systematic reviews and meta-analyses have investigated the effect of esketamine on sedation or non-intubated anesthesia (Chen H et al., 2023; Huang et al., 2023; Lian et al., 2023). Unlike our review, which aimed to include all combinations of intravenous esketamine, these studies focused specifically on the safety and efficacy of esketamine-propofol combination in comparison to other drug regimens. Our main findings were generally consistent with these three studies, except for one study by Huang et al., which included seven RCTs with 808 patients and reported no significant differences in respiratory depression and body movement with esketamine administration for procedural sedation, without providing a rationale for these finding (Huang et al., 2023). In addition, Chen H et al. included data only from adults, analyzed 14 RCTs and demonstrated that the esketamine-propofol combination provided more stable haemodynamic indices during induction of non-intubated anaesthesia (Chen H et al., 2023). Lian et al., pooling data from 18 RCTs involving 1962 patients, observed that the addition of esketamine to propofol significantly reduced recovery time compared with the saline group, but not compared with the opioid group. They further demonstrated that esketamine significantly lowered the required dose of propofol and the risk of overall complications when compared with both the saline and opioid groups (Lian et al., 2023).

In children, this study first demonstrated that esketamine adjunct to propofol sedation probably caused a lower risk of hypotension but a higher risk of visual disturbance and dizziness. Unlike in adults, the combined use of esketamine and propofol in children provided a limited benefit on the incidence of oxygen desaturation. This finding was consistent with that reported in two systematic reviews with ketamine-propofol combination, indicating only a reduced risk of hypotension and/or bradycardia but not oxygen desaturation in the pediatric population (Foo et al., 2020; Hayes et al., 2021). The possible explanation for these findings is the different respiratory physiology of children such as vulnerable airways, low functional residual capacity of the lungs, poor oxygen reserves, and high oxygen consumption and basal metabolic rate, which makes them more susceptible to respiratory depression from anesthetics (Zheng (b) et al., 2023; Zhong et al., 2023). All respiratory depression events were alleviated by airway management or mask oxygen delivery, and no

Outcome indicators	Studies	RR [95%]	<i>p</i> -value	^{2(%)}
Oxygen desaturation				
esketamine≤0.5 mg/kg	5 Wang et al. (2022); Xu et al. (2022); Zheng et al. (2023); Zheng et al. (2022); Zhong et al. (2023)	0.63 [0.29, 1.37]	p = 0.24	44
esketamine>0.5 mg/kg	2 Wang et al. (2022); Zheng et al. (2022)	0.53 [0.17, 1.73]	<i>p</i> = 0.30	0
Hypotension				
esketamine≤0.5 mg/kg	3 Wang et al. (2022); Xu et al. (2022); Zheng et al. (2022)	0.73 [0.45, 1.18]	<i>p</i> = 0.19	0
esketamine>0.5 mg/kg	2 Wang et al. (2022); Zheng et al. (2022)	0.33 [0.15, 0.75]	<i>p</i> = 0.008	12
Visual disturbance				
esketamine≤0.5 mg/kg	3 Wang et al. (2022); Zheng et al. (2022); Zheng et al. (2022)	6.74 [2.19, 20.79]	<i>p</i> = 0.0009	0
esketamine>0.5 mg/kg	2 Wang et al. (2022); Zheng et al. (2022)	5.40 [1.46, 19.93]	<i>p</i> = 0.01	37
Dizziness				
esketamine≤0.5 mg/kg	4 Wang et al. (2022); Zheng et al. (2022); Zheng et al. (2022); Zhong et al. (2023)	1.72 [0.98, 3.02]	<i>p</i> = 0.06	4
esketamine>0.5 mg/kg	2 Wang et al. (2022); Zheng et al. (2022)	2.36 [1.34, 4.18]	<i>p</i> = 0.003	0
Nausea and/or vomiting				
esketamine≤0.5 mg/kg	5 Wang et al. (2022); Xu et al. (2022); Zheng et al. (2022); Zheng et al. (2022); Zhong et al. (2023)	0.33 [0.09, 1.24]	<i>p</i> = 0.10	0
esketamine>0.5 mg/kg	3 Pees et al. (2003); Wang et al. (2022); Zheng et al. (2022)	1.05 [0.33, 3.30]	<i>p</i> = 0.93	0

TABLE 5 Children: esketamine dose subgroup analysis (<0.5 mg/kg versus >0.5 mg/kg).

serious complications occurred in children among the included studies (Wang et al., 2022; Xu (b) et al., 2022; Zheng (b) et al., 2023; Zheng et al., 2022; Zhong et al., 2023).

Another concern about esketamine usage is the psychic emergence reactions that manifest as vivid dreaming; extracorporeal experiences; and illusions with excitement, confusion, euphoria, and fear, and these are often accompanied by auditory and visual disturbances (Miller, 2006; Zhuang et al., 2009). They occur in the first hour of emergence and usually abate within one to several hours (Miller, 2006; Zhuang et al., 2009). Our results showed that the administration of esketamine to adults increased the incidence of psychiatric symptoms. These esketamine-related psychiatric symptoms did not require additional medical support in any of the included studies. Additionally, our study also observed similar awakening, recovery, and orientation recovery times in adults.

It is difficult for young children to express their experience and to self-report potential psychiatric symptoms (Xu (b) et al., 2022). Thus, adverse reactions such as visual disturbance (usually complaints of diplopia), dizziness, and emergence delirium were assessed instead in children. The incidence of visual disturbance and dizziness varied from 8% to 34.78% and 0%–73.3%, respectively, possibly depending on age, esketamine dose, and different surgical procedures among the included studies (Wang et al., 2022; Xu (b) et al., 2022; Zheng (b) et al., 2023; Zheng et al., 2022; Zhong et al., 2023). Furthermore, we found that visual disturbance was associated with esketamine regardless of its doses, while dizziness was associated with esketamine >0.5 mg/kg in this study. Those two postoperative complications were self-limited and did not require intervention among the included studies (Wang et al., 2022; Zheng (b) et al., 2022; Zhong et al., 2022; Zhong et al., 2022; Zhong et al., 2022; Zheng et al., 2022; Zheng te al., 2022; Zheng et al., 2023).

incidence of emergence delirium (assessed using pediatric anesthesia emergence delirium [PAED] scores) in our study should be interpreted with caution. In contrast to previous studies, one metaanalysis that combined one pediatric study and two adults studies observed that esketamine-propofol combination was associated with an increased risk of emergence agitation (not based on PAED scores) (Huang et al., 2023). It is thought that visual disturbance or dizziness may influence the recovery quality of children (Wang et al., 2022; Zhong et al., 2023). However, no significant difference was found in awakening and recovery time in our review.

Combination with propofol is the most common drug regimen of esketamine for sedation or analgesia, and dexmedetomidine and remimazolam were also added to esketamine in adults in two included studies (Lu et al., 2022; Lin et al., 2023). Dexmedetomidine, a highly selective a2-adrenergic agonist, and remimazolam, a short-acting benzodiazepine, both have fewer cardiovascular and respiratory side effects than propofol (Kim and Fechner, 2022; Zhang et al., 2024). Interestingly, a subgroup analysis of esketamine regimens revealed a significant reduction in the risk of oxygen desaturation, hypotension and bradycardia only with the esketamine-propofol combination but not with the esketamine-dexmedetomidine and -remimazolam combinations. Clinical heterogeneity, sample size and limited number of studies may contribute to the discrepancies in the subgroup analysis of esketamine-based regimens. The results of the subgroup analyses should be interpreted with caution. Further research, particularly RCTs with large sample sizes, is warranted to clarify the impact of esketamine in combination with non-propofol agents on the safety and efficacy of sedation and analgesia.

Our study has some limitations: (i) We did not stratify the main analysis by different types of surgical procedures and drug

regimens of the control group. This allowed us to broaden the applicability of the findings beyond a specific context. However, these factors may have caused heterogeneity among some analyses. Other factors such as the different definitions of some outcomes and strategies of esketamine and propofol administration may have also contributed to heterogeneity. (ii) Twenty-three of the 25 included studies (92%) were performed in China, which may have led to bias in the results. (iii) Some continuous variables (such as propofol consumption, awakening time, recovery time, and orientation recovery time) of the included studies were reported as medium or with different measurement units, making them unsuitable for direct data merging (Cui et al., 2023; Eberl et al., 2020; Feng (b) et al., 2022; Ma et al., 2024; Si et al., 2024; Song et al., 2023; Wang et al., 2022; Wang et al., 2019; Xu (a) et al., 2022; Xu (b) et al., 2022; Yang et al., 2022; Zhan et al., 2022; Zheng et al., 2022; Zhong et al., 2023). In our study, these data were excluded from the metaanalysis because we failed to obtain raw data from the authors. After qualitative analysis of these data, we found that esketamine groups was associated with lower propofol consumption in all 10 included studies that were ineligible for the meta-analysis (Eberl et al., 2020; Feng (b) et al., 2022; Ma et al., 2024; Song et al., 2023; Wang et al., 2022; Xu (a) et al., 2022; Xu (b) et al., 2022; Zhan et al., 2022; Zheng et al., 2022; Zhong et al., 2023). In addition, three of the seven "inappropriate" studies showed the significantly shorter awakening time and/or recovery time with esketamine administration (Wang et al., 2019; Eberl et al., 2020; Yang et al., 2022; Zheng et al., 2022; Cui et al., 2023; Ma et al., 2024; Si et al., 2024). (iv) Almost 90% of the included studies (22 out of 25) used drug regimens that comprised esketamine and propofol. We could perform the subgroup analysis of esketamine regimens for some outcomes in adults. Future studies are needed to explore the effect of different esketamine combinations on sedation or anesthesia. (v) Publication bias may exist for oxygen desaturation, hypotension, hypertension, and psychiatric symptoms by visual inspection of funnel plots, suggesting the need for cautious interpretation of results.

5 Conclusion

This study showed that intravenous esketamine combinations probably reduced the incidence of several cardiorespiratory depression events (hypotension, bradycardia, and oxygen desaturation); injection pain; body movement; and propofol requirement, but increased the risk of psychiatric symptoms in adults who have undergone different surgical procedures outside the operating room. However, subgroup analysis indicated that the incidence of hypotension, bradycardia, and oxygen desaturation in adults was significantly reduced only with the esketamine and propofol combination. In addition, this study also suggested that the combined use of esketamine and propofol may cause a lower risk of hypotension (esketamine>0.5 mg/kg), but a higher risk of visual disturbance and dizziness (esketamine>0.5 mg/kg) in children who have received sedation or analgesia outside the operating room. Although these short-term side effects usually do not require additional intervention, clinicians should be aware of the potential psychiatric symptoms of esketamine. Given the limited number of studies, future research is needed, particularly RCTs with substantial cohorts, to elucidate the effect of esketamine when combined with agents other than propofol on the safety and effectiveness of sedation and analgesia protocols.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

ZK: Data curation, Writing–original draft, Writing–review and editing. WM: Data curation, Writing–review and editing. YD: Data curation, Writing–review and editing. PZ: Data curation, Writing–original draft, Writing–review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Science and Technology Plan Project of Sichuan Province, China [2022YFS0439], the Cadres Health research topic Sichuan Province, China [2022-217] and the youth talent fund project of Sichuan Provincial People's Hospital [2021QN16].

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1287761/ full#supplementary-material

References

Boriosi, J. P., Eickhoff, J. C., Klein, K. B., and Hollman, G. A. (2017). A retrospective comparison of propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI sedation. *Paediatr. Anaesth.* 27 (1), 52–59. doi:10.1111/pan.13041

Chen, H., Ding, X., Xiang, G., Xu, L., Liu, Q., Fu, Q., et al. (2023). Analysis of the efficacy of subclinical doses of esketamine in combination with propofol in non-intubated general anesthesia procedures - a systematic review and meta-analysis. *Bmc. Anesthesiol.* 23 (1), 245. doi:10.1186/s12871-023-02135-8

Chen, J., Zou, X., Hu, B., Yang, Y., Wang, F., Zhou, Q., et al. (2022). Effect of different doses of esketamine compared with fentanyl combined with propofol on hypotension in patients undergoing painless abortion surgery: a prospective, randomized, double-blind controlled clinical trial. *Bmc. Anesthesiol.* 22 (1), 305. doi:10.1186/s12871-022-01848-6

Chen, Y., Chen, J., Wang, Q., Lyu, H., Chen, X., Liu, R., et al. (2023). Safety and tolerability of esketamine in propofol based sedation for endoscopic variceal ligation with or without injection sclerotherapy: randomized controlled trial. *Dig. Endosc.* 35, 845–854. doi:10.1111/den.14539

Cui, S., Huang, P., Wei, Z., Guo, T., Zhang, A., and Huang, L. (2023). Esketamine combined with propofol tci versus propofol tci for deep sedation during endobronchial ultrasound-guided transbronchial needle aspiration: a prospective, randomized, and controlled trial. *Int. J. Clin. Pract.* 2023, 1155126. doi:10.1155/2023/1155126

De Vries, L. J., Veeger, N., Van Roon, E. N., and Lameijer, H. (2023). Low-dose ketamine or opioids combined with propofol for procedural sedation in the emergency department: a systematic review. *Eur. J. Emerg. Med.* 30 (4), 244–251. doi:10.1097/mej. 000000000001046

Eberl, S., Koers, L., van Hooft, J., de Jong, E., Hermanides, J., Hollmann, M. W., et al. (2020). The effectiveness of a low-dose esketamine versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatography: a randomised controlled multicentre trial. *Eur. J. Anaesthesiol.* 37 (5), 394–401. doi:10.1097/eja.00000000001134

Feng, M., Shi, G., Cui, W., Zhang, N., Xie, Q., and Zhang, W. (2022a). The median effective concentration of propofol in combination with different doses of esketamine during gastrointestinal endoscopy in adults. *Front. Pharmacol.* 13, 1034236. doi:10. 3389/fphar.2022.1034236

Feng, Y., Du, T., Wang, J., and Chen, Z. (2022b). Low dose of esketamine combined with propofol in painless fibronchoscopy in elderly patients. *Med. Baltim.* 101 (50), e31572. doi:10.1097/md.00000000031572

Foo, T. Y., Mohd Noor, N., Yazid, M. B., Fauzi, M. H., Abdull Wahab, S. F., and Ahmad, M. Z. (2020). Ketamine-propofol (Ketofol) for procedural sedation and analgesia in children: a systematic review and meta-analysis. *Bmc. Emerg. Med.* 20 (1), 81. doi:10.1186/s12873-020-00373-4

Hayes, J. A., Aljuhani, T., De Oliveira, K., and Johnston, B. C. (2021). Safety and efficacy of the combination of propofol and ketamine for procedural sedation/ anesthesia in the pediatric population: a systematic review and meta-analysis. *Anesth. Analg.* 132 (4), 979–992. doi:10.1213/ane.000000000004967

Higgins, J. P., and Deeks, J. J. (2011). "Chapter 7: selecting studies and collecting data," in *Cochrane handbook for systematic reviews of interventions*. Editors J. P. T. Higgins and S. Green (The Cochrane Collaboration). Version 5.1.0 (updated March 2011).

Hinkelbein, J., Schmitz, J., Lamperti, M., and Fuchs-Buder, T. (2020). Procedural sedation outside the operating room. *Curr. Opin. Anaesthesiol.* 33 (4), 533–538. doi:10. 1097/aco.00000000000885

Huang, X., Lin, F., Chen, Q., and Hu, X. (2023). Safety and efficacy of the combination of esketamine and propofol in procedural sedation/analgesia: a systematic review and meta-analysis. *Minerva. Anestesiol.* 89, 680–689. doi:10. 23736/60375-9393.23.17100-8

Jo, Y. Y., and Kwak, H. J. (2019). Sedation strategies for procedures outside the operating room. *Yonsei. Med. J.* 60 (6), 491–499. doi:10.3349/ymj.2019.60.6.491

Kim, S. H., and Fechner, J. (2022). Remimazolam - current knowledge on a new intravenous benzodiazepine anesthetic agent. *Korean J. Anesthesiol.* 75 (4), 307–315. doi:10.4097/kja.22297

Li, C. Y., Chen, Z. Y., He, H. F., Wang, H. G., and Xu, L. M. (2022). A subclinical dose of esketamine pretreatment for propofol and rocuronium injection pain. *Asian. J. Surg.* 45 (12), 3038–3039. doi:10.1016/j.asjsur.2022.07.103

Lian, X., Lin, Y., Luo, T., Jing, Y., Yuan, H., and Guo, Y. (2023). Efficacy and safety of esketamine for sedation among patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis. *Bmc. Anesthesiol.* 23 (1), 204. doi:10.1186/ s12871-023-02167-0

Lin, Z., Li, S., Zhou, Y., Lu, X., Yang, B., Yu, Z., et al. (2023). A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial. *Bmc. Anesthesiol.* 23 (1), 304. doi:10.1186/ s12871-023-02266-y

Liu, X., Xiao, Q., and Zhuang, S. (2023). Comparison of propofol-esketamine versus propofol for anesthesia in gastroscopy: a double-blind, randomized controlled clinical trial. *Front. Med. (Lausanne).* 10, 1184709. doi:10.3389/fmed.2023.1184709

Lu, C., Ren, J., Guo, X., and Qian, J. (2022). Effects of remimazolam combined with esketamine anesthesia on circulatory and respiratory function during painless gastroenteroscopy. *Contrast. Media. Mol. Imaging.* 2022, 1079099. doi:10.1155/2022/1079099

Ma, Y., Wang, J., Yang, Y., and Yao, M. (2024). Efficacy and safety of esketamine combined with propofol for curative endoscopic resection in colorectum: a prospective, randomized controlled trial. *Bmc. Anesthesiol.* 24 (1), 96. doi:10.1186/s12871-024-02475-z

Miller, R. D. (2006). Miller's anesthesia. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 171-183.

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., and Group, P. (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int. J. Surg.* 8 (5), 336–341. doi:10.1016/j.ijsu.2010.02.007

Nakao, S., Nagata, A., Miyamoto, E., Masuzawa, M., Murayama, T., and Shingu, K. (2003). Inhibitory effect of propofol on ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices is mediated by GABAA receptor activation. *Anaesthesiol. Scand.* 47 (3), 284–290. doi:10.1034/j.1399-6576.2003.00040.x

Nie, J., Chen, W., Jia, Y., Zhang, Y., and Wang, H. (2023). Comparison of remifentanil and esketamine in combination with propolo for patient sedation during fiberoptic bronchoscopy. *Bmc. Pulm. Med.* 23 (1), 254. doi:10.1186/s12890-023-02517-1

Pees, C., Haas, N. A., Ewert, P., Berger, F., and Lange, P. E. (2003). Comparison of analgesic/sedative effect of racemic ketamine and S(+)-ketamine during cardiac catheterization in newborns and children. *Pediatr. Cardiol.* 24 (5), 424–429. doi:10. 1007/s00246-002-0356-4

Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., and Saari, T. I. (2016). Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin. Pharmacokinet.* 55 (9), 1059–1077. doi:10.1007/s40262-016-0383-6

Pino, R. M. (2007). The nature of anesthesia and procedural sedation outside of the operating room. *Curr. Opin. Anaesthesiol.* 20 (4), 347–351. doi:10.1097/ACO. 0b013e32827035c7

Rathi, G. V., Padawe, D., Takate, V., Dighe, K., Bansode, K. K., and Narwade, A. U. (2022). Comparative evaluation of ease of dental treatment and clinical efficiency of midazolam vs midazolam and ketamine combination for sedation in young uncooperative pediatric patients: a systematic review. *Int. J. Clin. Pediatr. Dent.* 15 (6), 680–686. doi:10.5005/jp-journals-10005-2456

Ren, Y. L., Yuan, J. J., Xing, F., Zhu, L. N., and Zhang, W. (2023). Effects of different doses of esketamine on pain sensitivity of patients undergoing thyroidectomy: a randomized controlled trial. *Ther* 12 (3), 739–750. doi:10.1007/s40122-023-00488-z

Si, J., Li, X., Wang, Y., Feng, N., and Cui, M. (2024). Effects of adding low-dose esketamine to sufentanil and propofol sedation during cervical conization: a single-centre, randomized controlled trial. *Bmc. Anesthesiol.* 24 (1), 15. doi:10.1186/s12871-023-02389-2

Song, N., Yang, Y., Zheng, Z., Shi, W. C., Tan, A. P., Shan, X. S., et al. (2023). Effect of esketamine added to propofol sedation on desaturation and hypotension in bidirectional endoscopy: a randomized clinical trial. *JAMA. Netw. Open* 6 (12), e2347886. doi:10.1001/jamanetworkopen.2023.47886

Wang, J., Hu, W., Zhao, X., Ren, W., Huang, X., and Zhang, B. (2022). Sedative effect and safety of different doses of S-ketamine in combination with propofol during gastroduodenoscopy in school-aged children: a prospective, randomized study. *Bmc. Anesthesiol.* 22 (1), 346. doi:10.1186/s12871-022-01885-1

Wang, J., Huang, J., Yang, S., Cui, C., Ye, L., Wang, S. Y., et al. (2019). Pharmacokinetics and safety of esketamine in Chinese patients undergoing painless gastroscopy in comparison with ketamine: a randomized, open-label clinical study. *Drug. Des. devel. Ther.* 13, 4135–4144. doi:10.2147/dddt.s224553

Xin, Z., Wang, P., Wang, N., Li, B., Yu, T., Gong, K., et al. (2024). Comparison of three intravenous sedation techniques used for extracting mandibular third molars in dental patients. *J. Hard Tissue Biol.* 33 (1), 61–66. doi:10.2485/jhtb.33.61

Xu, C., Wei, X., Zhang, C., Huang, X., Lan, H., Xu, Y., et al. (2022). Esketamine prevents propofol-induced injection pain: randomized controlled trial. *Front. Pharmacol.* 13, 991559. doi:10.3389/fphar.2022.991559

Xu, S. X., Shan, X. S., Gao, J. M., Liu, H. X., Chen, W. R., Gao, S. S., et al. (2022). Effect of esketamine vs dexmedetomidine adjunct to propofol sedation for pediatric 3Tesla magnetic resonance imaging: a randomized, double-blind, controlled trial. *Eur. J. Med. Res.* 27 (1), 258. doi:10.1186/s40001-022-00890-x

Xu, Y., Zheng, Y., Tang, T., Chen, L., Zhang, Y., and Zhang, Z. (2022). The effectiveness of esketamine and propofol versus dezocine and propofol sedation during gastroscopy: a randomized controlled study. *J. Clin. Pharm. Ther.* 47 (9), 1402–1408. doi:10.1111/jcpt.13678

Yang, H., Zhao, Q., Chen, H. Y., Liu, W., Ding, T., Yang, B., et al. (2022). The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: a randomized controlled trial. *Br. J. Clin. Pharmacol.* 88 (3), 1279–1287. doi:10.1111/bcp.15072

Zhan, Y., Liang, S., Yang, Z., Luo, Q., Li, S., Li, J., et al. (2022). Efficacy and safety of subanesthetic doses of esketamine combined with propofol in painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial. *Bmc. Gastroenterol.* 22 (1), 391. doi:10.1186/s12876-022-02467-8

Zhang, W., Wang, L., Zhu, N., Wu, W., and Liu, H. (2024). A prospective, randomized, single-blinded study comparing the efficacy and safety of dexmedetomidine and propofol for sedation during endoscopic retrograde cholangiopancreatography. *BMC Anesthesiol.* 24 (1), 191. doi:10.1186/s12871-024-02572-z

Zheng, L., Wang, Y., Ma, Q., Liang, W., Zhang, X., Ren, Z., et al. (2023a). Efficacy and safety of a subanesthetic dose of esketamine combined with propofol in patients with obesity undergoing painless gastroscopy: a prospective, doubleblind, randomized controlled trial. *Drug Des. Dev. Ther.* 17, 1347–1356. doi:10. 2147/DDDT.S408076

Zheng, X., Huang, J., Wei, S., Tao, Y., Shen, Y., Wang, Y., et al. (2023b). Efficacy and safety comparison of esketamine-propofol with nalbuphine-

propofol for upper gastrointestinal endoscopy in children: a multi-center randomized controlled trial. *Front. Pediatr.* 11, 1126522. doi:10.3389/fped. 2023.1126522

Zheng, X. S., Shen, Y., Yang, Y. Y., He, P., Wang, Y. T., Tao, Y. Y., et al. (2022). ED(50) and ED(95) of propofol combined with different doses of esketamine for children undergoing upper gastrointestinal endoscopy: a prospective dose-finding study using up-and-down sequential allocation method. *J. Clin. Pharm. Ther.* 47 (7), 1002–1009. doi:10.1111/jcpt.13635

Zhong, Y., Jiang, M., Wang, Y., Su, T., Lv, Y., Fan, Z., et al. (2023). Evaluating efficacy and safety of sub-anesthetic dose esketamine as an adjuvant to propofol/ remifentanil analgosedation and spontaneous respiration for children flexible fibreoptic bronchoscopy: a prospective, double-blinded, randomized, and placebo-controlled clinical trial. *Front. Pharmacol.* 14, 1184663. doi:10.3389/ fphar.2023.1184663

Zhuang, X. L., Zeng, Y. M., and Chen, B. L. (2009). *Modern Anesthesiology*. 3rd ed. Beijing: People's Medical Publishing House, 503–509.